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ABSTRACT 
The number of antimicrobials available to treat bacterial respiratory disease in goats is 
extremely limited.  Currently, only ceftiofur has been approved for use in this species.  
Concerns over the development of antimicrobial resistance in bacteria that infect humans 
have led to proposed restrictions on the use of this drug in food-producing animals.  
Tulathromycin, a triamilide macrolide antibiotic found to be safe and effective against 
respiratory bacterial pathogens in cattle and swine, was formulated to enhance persistence in 
lung tissue.  The Minor Use Animal Drug Program (National Research Support Project-7) 
identifies and supports research directed at meeting the Food and Drug Administration 
(FDA) requirements for drug approval in minor species or for minor uses in major species.  
The current work was undertaken to support FDA approval of tulathromycin in the caprine 
species by providing an assessment of target animal drug safety, drug tissue elimination, and 
drug efficacy.  Tulathromycin had no detrimental clinical effects, even in animals treated 
with 5X the proposed label dose for three times the proposed label duration.  Tissue 
elimination and pharmacokinetic behavior paralleled that found in both cattle and swine.  
Efficacy analysis was conducted on the clinical effect and pharmacokinetic behavior of 
tulathromycin in goats as well as in vitro antimicrobial effects on bacterial isolates recovered 
from goats. Bacteria isolated from goats with clinical cases of pneumonia were highly 
susceptible to this drug in several in vitro assays.  Overall, this research demonstrated that 
tulathromycin would be a safe, effective, and valuable medication in the treatment of 
bacterial pneumonia in goats.
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CHAPTER 1.  GENERAL INTRODUCTION 
INTRODUCTION 
Goats (Capra aegagrus hircus) are an important small ruminant species both in the 
United States and around the world.  The Food and Agriculture Organization of the United 
Nations estimates that globally over four million pounds of goat meat and 15 million pounds 
of goat milk are sold annually; these values underestimate true production since many goat 
products are consumed locally (http://faostat.fao.org/site/569/default.aspx#ancor, 7-13-10).  
The National Agricultural Statistics Service of the USDA estimated goat numbers in the 
United States as of January, 2010, at 3.04 million head, with over 2.5 million of these being 
meat goats.
1
  While these numbers are small compared to other livestock species (93.7 
million cattle and 66.8 million swine), the caprine species represents an important segment of 
U.S. agriculture.  In addition to providing food and fiber products, goats are frequently used 
for additional activities such as brush control.  As browsers they are fit to survive on plant 
material that may be ignored by other ruminant species, and their use in vegetation 
management and to control noxious plants represents a major contribution of this species 
(Debeuf et al., 2004; Glimp, 1995).  Although meat goat production is rarely the sole source 
of income in a livestock enterprise, it can contribute to the overall economic viability of these 
operations. 
While goat production is a growing segment of U.S. agriculture, the number of FDA-
approved medications available to treat this species is severely limited (Fajt, 2001; Fajt, 
                                                 
1
 USDA Economics, Statistics, and Marketing Information System, National Agricultural Statistics Service 
Report, July 24, 2009 and Jan 28, 2000. 
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2003; Webb et al., 2004).  The approval process for a new animal medication has very 
specific requirements.  The time to complete this process had been estimated at 8-10 years 
and the cost at $20-40 million; therefore, it is not cost effective for pharmaceutical 
companies to pursue these requirements for minor species use (United States Department of 
Agriculture National Research Support Project 7, 2007).   Consequently, many drugs are 
administered to goats in an extra-label manner with no scientific information on drug 
behavior, potential toxicity, and adequate withdrawal periods for drug removal from products 
marketed for human consumption (Berge et al., 2006; Fajt, 2001; Fajt, 2003).   
Bacterial pneumonia is a frequent health problem in small ruminants (Ackermann & 
Brogden, 2000; Washburn et al., 2007; Yener et al., 2009).  Mannheimia haemolytica, 
Bibersteinia (Pasteurella) trehalosi, Pasteurella multocida, and Mycoplasma spp. are the 
most frequently identified bacterial pathogens in goats with clinical respiratory disease 
(Berge et al., 2006; Brogden et al., 1998; Washburn et al., 2007; Yener et al., 2009; Zamri-
Saad & Mera, 2001).  Currently the cephalosporin ceftiofur is the only antimicrobial 
approved for use in goats (Fajt, 2001; Fajt, 2003; Washburn et al., 2007).  Several limitations 
exist with use of this antibiotic, including the need for daily administration to maintain 
therapeutic concentrations and the lack of efficacy associated with Mycoplasma infections 
(Rosenbusch et al., 2005).  Concerns over antimicrobial resistance patterns in human 
bacterial isolates and their potential association with antibiotic use in food animal species had 
led to potential legislative restrictions that may be placed on use of this drug class in 
livestock (Nolen, 2009).  Such restrictions would remove the only drug approved for use in 
goats.   
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Tulathromycin is a novel triamilide in the macrolide class shown to be safe and effective 
against bacterial respiratory pathogens in cattle and swine (Benchaoui et al., 2004; Evans, 
2005; Hart et al., 2006; Nowakowski et al., 2004).  Its unique structural properties permit 
rapid dissemination out of plasma and extended residence time in tissues, primarily the lung 
(Benchaoui et al., 2004; Evans, 2005; Nowakowski et al., 2004).  Since goats are susceptible 
to many of the same bacterial pathogens as cattle, tulathromycin may prove useful in the 
caprine species.   
The primary objective of this work was to assess tulathromycin as a therapeutic agent in 
goats with the intent to partially meet FDA/CVM requirements for a label claim in this 
species.  All studies were conducted according to Good Laboratory Practice standards (21 
CFR Part 58).  Studies were monitored by a Food and Drug Administration (FDA) 
representative to ensure adherence to GLP standards.  The individual studies were conducted 
to address the safety of tulathromycin in goats; to assess the tissue depletion of tulathromycin 
in goats to provide data useful for establishing an appropriate withdrawal time for this drug 
in potential food products; and to utilize a method of establishing efficacy of tulathromycin 
against major respiratory pathogens by studying pharmacokinetic and pharmacodynamic 
behavior of this drug in goats. 
DISSERTATION ORGANIZATION 
This dissertation is organized into six chapters including four separate scientific 
manuscripts.  Chapter 1 provides a brief introduction on the reasons for conducting the 
present research, an overview of the dissertation format and a literature review with 
background information describing the reasons for conducting this research.  References 
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cited in the general introduction and the literature review are listed at the end of Chapter 1 
and formatted to the style of the Journal of Veterinary Pharmacology and Therapeutics.  
Chapter 2 reports on the assessment of the safety of tulathromycin administration in goats 
and evaluated animals at the label dose, 3 times the label dose, and 5 times the label dose for 
three times the recommended duration of therapy for cattle and swine.  This manuscript was 
published in Journal of Veterinary Pharmacology and Therapeutics.  Tissue residue 
evaluation and an estimation of tulathromycin content in lung (the target tissue) are covered 
in Chapter 3 in order to provide data to FDA for the establishment of a withdrawal time for 
tulathromycin in goats.   This manuscript is under review by the co-authors of the Food 
Animal Residue Avoidance Databank (FARAD) and will be submitted to the Journal of 
Veterinary Pharmacology and Therapeutics.  In Chapter 4, pharmacokinetic behavior and 
modeling assessment of tulathromycin was conducted on three study groups of goats.  This 
paper has been accepted with revisions by the Journal of Veterinary Pharmacology and 
Therapeutics. Chapter 5 contains a review of MIC values for bacterial isolates collected from 
diseased tissues in goats with clinical pneumonia.  The purpose of this evaluation was to 
assess susceptibility to tulathromycin although a panel of antimicrobial drugs was used.  In 
addition, minimum bactericidal concentration (MBC) assessments and kinetic killing assays 
were performed on a subset of isolates to further demonstrate bacterial sensitivity to 
tulathromycin.  This manuscript will be submitted to the Journal of the American Veterinary 
Medical Association.  Chapter 6 has some final conclusions and implications of the research 
that may lead to the ultimate goal of FDA approval of this drug in caprines.   
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LITERATURE REVIEW 
Industry background 
The domestic goat (Capra aegagrus hircus) has many characteristics that make it a 
valuable livestock species.  As primary browsers, goats can survive on range land and plant 
species that other ruminants cannot.  According to the Food and Agriculture Organization of 
the United Nations (http://faostat.fao.org/site/339/default.aspx, 6-25-10), goat meat is the 
most consumed meat in the world, and the world’s goat population is over 861,000,000 head.  
In the United States, goats are utilized for production of meat, milk and milk products, hair 
and fiber products, for brush control, and as companion animals (Glimp, 1995).   Ethnic and 
faith-based groups that consume goat products have increased 100% in this country over the 
last 10 years, and the demand for goat products to supply these niche markets has increased 
as well (Solaiman, 2007).  The Hispanic population alone increased 57.9% from 1990 to 
2000, accompanied by increases in Asian, African, and Muslim populations.   In 2005, the 
United States was the number one importer of goat products in the world, accounting for 
18.2% of the total market share.  Nearly 25 million pounds of goat meat were imported into 
this country in 2006 (Solaiman, 2007).  From 1997 to 2002, the number of U.S. farms selling 
goats increased 145.3% from 29,237 to 43,495, demonstrating expansion of U.S. goat 
production in response to this increasing demand (National Agricultural Statistics Service, 
USDA, 2010).  While goats represent a growing segment of agriculture, their numbers are far 
lower than those of other livestock species and many of their health issues cannot be 
addressed with FDA-approved medications.   
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Food and Drug Administration Background 
The Food and Drug Administration Center for Veterinary Medicine (FDA CVM) governs 
the evaluation and approval of medications to be used in animals.  Initially the investigator 
conducting the research must receive FDA approval to administer the drug for experimental 
purposes under the Investigational New Animal Drug (INAD) exemption.  The research must 
be conducted under Good Laboratory Practices (Code of Federal Regulations Title 21, 2009).  
A New Animal Drug Application (NADA) review assesses data in three main areas.  A 
safety evaluation is conducted in the target species to ensure there are no adverse effects 
associated with its administration.  A human food safety study that evaluates drug 
elimination in specific tissues must be performed in animals that produce products which 
could be consumed by humans.  Finally, the drug must be shown to be effective against the 
condition for the label claim addressed in the application. 
(http://www.fda.gov/AnimalVeterinary/DevelopmentApprovalProcess/NewAnimal-
DrugApplications/ucm146121.htm, 3/25/10).  In addition, studies on bioavailability, 
injection site tolerance, oral toxicity in laboratory animals, effects on fetal tissues in 
laboratory animals, microbial mutation rates, mammalian cell line cytotoxicity, radiotracer 
tissue depletion, comparison metabolism, microbial food safety, and induction of 
antimicrobial resistance transfer may also be components of an NADA portfolio (NADA, 
141-244, 2005). 
Investigations designed to meet these requirements can be costly and difficult to 
accomplish with no guarantee to the pharmaceutical company of any return on investment.  
Estimates for drug approval on a new medication can reach as high as $40 million and on the 
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addition of a label claim for an existing medication as high as $10 million (United States 
Department of Agriculture National Research Support Project 7, 2008).  Since each 
medication must be shown to adequately meet these requirements for an individual species 
and a specific condition, potential sales must provide sufficient incentive to a pharmaceutical 
company to justify the financial and time outlay for this process.  Consequently, very few 
medications are labeled for use in individual species such as goats that do not represent a 
major segment of U.S. agriculture.    
Species for which there are limited labeled medications often must be treated in an 
“extra-label” manner.  The FDA recognized that use of medications in this manner could 
result in unsafe consequences for animals being treated in addition to potential residues 
entering the human food chain.  In 1976, the FDA formed a committee to address needs for 
medications to treat less populous species or uncommon conditions.  The IR-4 Animal Drug 
Program established in 1982 formed a partnership between animal industries and the FDA to 
identify and secure drug approvals for minor species (United States Department of 
Agriculture National Research Support Project7, 2007).   
The FDA CVM-defined major species are cattle, swine, horses, dogs, cats, and chickens, 
and turkeys (Fait, 2003; NADA, 141-244, 2005).  Species not included in this group are 
classified as “minor” because their numbers and industries are smaller than those of major 
species.  USDA estimates gross annual income from agricultural production of minor species 
at $9 billion per year (NADA, 141-244, 2005).  While the economic contribution from these 
industries is large as a whole, contributions from individual species for specific diseases in 
these groups frequently do not justify the outlay necessary to meet FDA medication approval.   
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By comparison, annual income from major U.S. agricultural industries are estimated at $76 
billion from cattle production, $16 billion from swine production, and $32 billion from 
poultry production (United States Department of Agriculture Economic Research Service, 
2010).  
The Animal Medicinal Drug Use Clarification Act (AMDUCA) enacted in 1994 provided 
veterinarians with the authority to prescribe medications “off-label” under a valid veterinary-
client-patient relationship in species or for conditions that do not have approved medications 
(Berge et al., 2006; Fajt, 2001; Fajt, 2003; Webb et al., 2004).  There are many restrictions in 
this directive, including the requirement for all prescribed drugs to be FDA-approved in at 
least one other species.  Certain drug classes are expressly prohibited from off-label use, and 
the utilization in minor species of feed additives and medications applied specifically to 
increase production is not permitted under AMDUCA.  Additionally, veterinarians who 
prescribe suitable medications are responsible for determining the appropriate dose for the 
species being treated and establishing an appropriate withdrawal period to prevent violative 
residues in potential human food products (Fajt, 2001; Fajt, 2003).  Medications approved for 
one species may not be appropriate for extra-label use in another species.  For example, the 
macrolide antibiotic tilmicosin is labelled for treatment of bacterial pneumonia in cattle and 
has been shown to be safe and effective in the treatment of respiratory disease in sheep; 
however, this medication may be cardiotoxic and potentially fatal when administered to goats 
(Christodoulopoulos et al., 2002; Jordan et al., 1993).  Data from controlled studies in the 
target species is invaluable to assist clinicians in the choice of a safe and effective therapeutic 
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that fulfills AMDUCA requirements and avoids entry of drug residues into the human food 
chain.   
Minor Species and Minor Use Program 
The Minor Use and Minor Species Animal Health Act of 2004 amended the Food, Drug, 
and Cosmetic Act to help facilitate the development of drugs for less common species and 
indications (United States Department of Agriculture National Research Support Project7, 
2007).  It provides additional classifications for these compounds that assist pharmaceutical 
companies in receiving drug approval with lower financial outlay.  A “conditional approval” 
description permits a company to release a drug to the market while providing additional 
time to collect efficacy data in the target species; a “designation” description allows a 
pharmaceutical company to apply for grants to offset the financial outlay needed to complete 
the work required to meet FDA approval; “indexing” applies to drugs that would be used so 
rarely that complete studies could not reasonably be conducted and does not cover drugs that 
would be used in food animal species.  Additionally, companies may be eligible for reduced 
or eliminated user fees associated with NADA.  The Office of the Minor Use/Minor Species 
(OMUMS) is responsible for the oversight of these procedures and communication with the 
Office of New Animal Drug Evaluation (ONADE).   
National Research Support Project 7 
National Research Support Projects (NRSP’s) were established by the USDA to provide 
support to organizations conducting research in a specific area or discipline.  The goal of 
these programs is to coordinate efforts and provide resources, information, materials, and 
facilities to accomplish research objectives in a defined discipline.  The NRSP-7 Minor Use 
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Animal Drug Program identifies animal drug needs in minor species and coordinates data 
sharing and dissemination between animal industries, pharmaceutical companies, and 
research institutions with the ultimate goal of facilitating FDA drug approval for these 
underserved species or conditions.  Currently 342 drug requests identified as valuable for use 
in minor species have been submitted to OMUMS for investigation, with over 100 of those 
drugs identified as urgently needed in minor species (United States Department of 
Agriculture National Research Support Project7, 2008).  Prioritization of drug needs and 
indications with the greatest potential impact across the range of minor species is critically 
evaluated to ensure research aimed at meeting FDA requirements for drug approval addresses 
the needs of the stakeholders involved in these industries. 
Macrolide antibiotics 
Tulathromycin is a novel macrolide antimicrobial with a triamilide structure found to be 
effective against bacterial respiratory pathogens in cattle and swine (Benchaoui et al., 2004; 
Nowakowski et al., 2004).  Since goats are susceptible to many of the same respiratory 
pathogens as cattle and the susceptibility of these agents to tulathromycin has been 
demonstrated in many in vitro and in vivo studies, tulathromycin was identified for 
investigation as a potentially suitable therapeutic agent against bacterial pneumonia in goats. 
The macrolide class of antibiotics contain a 14-, 15-, or 16-membered macrocyclic 
lactone ring to which amino sugars are attached (Alvarez-Elcoro & Enzler, 1999; Retsemea 
& Fu, 2001).   The unique structure of macrolides facilitates rapid dissemination from the 
central compartment (plasma) to lung tissues which make them useful in the treatment of 
bacterial pneumonia (Amsden, 2001; Williams & Sefton, 1993).  Natural macrolides were 
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originally isolated from Streptomyces; first generation, semi-synthetic macrolides such as 
erythromycin were derived from these bacterial analogues (Alvarez-Elcoro & Enzler, 1999; 
Evans, 2005) .  This class of antibiotic acts by binding to the 50S ribosomal subunit, 
preventing translocation of the growing peptide and blocking protein synthesis (Alvarez-
Elcoro & Enzler, 1999; Benchaoui, et al., 2004; Evans, 2005; Retsemea & Fu, 2001; 
Williams & Sefton, 1993).  Newer macrolides have been designed with modified 
configurations to enhance in vitro and in vivo antibacterial properties along with increasing 
bioavailability, lung tissue penetration, and extended tissue half-lives (Benchaoui, et al., 
2004; Retsemea & Fu, 2001).  The addition of a methyl group to the ring structure of 
azithromycin confers a two- to eight-fold increase in activity against Haemophilus influenzae 
over erythromycin (Retsemea & Fu, 2001).   
Due to the unique pharmacokinetic (PK) and pharmacodynamic (PD) properties resulting 
in rapid dissemination from plasma and into tissues, macrolide behavior and potential 
efficacy cannot be fully evaluated with plasma concentration analysis that is used to assess 
other antimicrobials (Amsden, 2001; Benchaoui et al., 2004; Nightengale, 1997; Veber et al., 
1993).  Other PK/PD parameters that can be calculated from a time-concentration curve for a 
specific drug can be used to estimate total drug exposure and have been used to describe 
efficacy of macrolides and are shown in Figure 1.1.  The time above minimum inhibitory 
concentration (T > MIC) for a specific pathogen correlates most directly with clinical 
efficacy in older macrolides (Nightengale, 1997; Veber et al., 1993).   This parameter, 
however, is not valid when evaluating newer macrolides such as azithromycin and 
dirithromycin (Benchaoui et al., 2004).  Tissue drug concentrations at the site of infection 
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may provide more relevant information to assess PK/PD activities of this drug class, 
particularly for novel compounds with enhanced lung persistence (Benchaoui et al., 2004; 
Evans, 2005).  The newer macrolides achieve high concentrations in granulocytes, 
lymphocytes, and monocytes which will be directed toward sites of inflammation/infection 
and increase effective therapeutic drug concentrations in critical locations (Amsden, 2001).  
An alternative PK/PD parameter, the area under the time-concentration curve (AUC) 
compared to the minimum inhibitory concentration (MIC) of a specific pathogen, provides a 
much more valuable assessment for these drugs (Amsden, 2001).  Frequently the AUC/MIC 
ratio is evaluated using both plasma and tissue analysis to assess potential macrolide efficacy. 
Tulathromycin Properties 
Tulathromycin is a novel macrolide that in vivo exists in a 9:1 ratio of  15-membered and  
13-membered ring structures containing two attached sugar moieties (Evans, 2005; 
Nowakowski et al., 2004; Gáler et al., 2004).  Both isoforms contain three amine groups at 
different locations on the molecule, placing tulathromycin in the triamilide group of 
macrolides (Evans, 2005).  The presence of amine groups is a characteristic of macrolides, 
including erythromycin which contains one amine group and azithromycin which contains 
two; however, the tribasic structure provides unique attributes to this molecule (Evans, 
2005).   One amine group is contained on the azalide ring while the other two are attached to 
the sugar molecules in separate regions of the structure.  Each amine may be neutral or 
positively charged so that each molecule can carry a charge of zero to 3+; all forms will exist 
in dynamic equilibrium depending on environmental pH (Evans, 2005; Nowakowski et al., 
2004).   
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In addition to impacting enhanced tissue and cellular penetration characteristic of all 
macrolides, this novel structure conveys desirable anti-bacterial properties particularly 
against Gram negative respiratory bacteria.  Cellular permeability is enhanced when 
molecules can exist in an un-ionized form (Goodman & Gilman, 2006).  In its triply-charged 
form, tulathromycin is thought to displace Mg
2+
 ions from the cell wall of many Gram 
negative bacterial pathogens and damage cell wall integrity (Evans, 2005; Nowakowski et 
al., 2004).  The molecules can then pass through the cell wall and into the periplasmic space, 
where equilibrium of the charged and uncharged molecules is re-established.  Uncharged 
molecules then penetrate the inner cell membrane of these bacteria and gain access to 
cytoplasmic ribosomes (Benchaoui et al., 2004; Evans, 2005).   As a macrolide, 
tulathromycin exerts its activity through binding to the 50S subunit of bacterial ribosomes 
and blocking peptidyl transferase which results in dissociation of transfer RNA (tRNA), 
cessation of peptide translocation, and blockage of protein synthesis (Benchaoui et al., 2004; 
Evans, 2005).  Although this drug is classified as bacteriostatic, it can also exhibit 
bactericidal activity at higher concentrations (Benchaoui et al., 2004; Evans, 2005; 
Nowakowski et al., 2004).  
As described earlier with other recently developed macrolides, standard 
pharmacodynamic assessment of antibiotic activity does not readily apply to tulathromycin 
(Benchaoui et al., 2004; Evans, 2005).  In addition, due at least in part to its lipophilic 
properties, tulathromycin demonstrates better tissue penetration and longer half-lives than 
older macrolides (Benchaoui et al., 2004; Evans, 2005).  This activity can provide unique 
therapeutic advantage in treating bacterial respiratory infections in livestock species.    
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Analysis of lung tissue homogenates provides an estimation of combined extracellular 
and intracellular drug concentrations but cannot differentiate between the two; however, in 
the case of macrolide antimicrobials, these values correlate well with magnitude of drug 
exposure at the site of infection (Benchaoui et al., 2004).  This provides better data on 
potential in vivo efficacy than serum or plasma concentrations in this drug class (Benchaoui 
et al., 2004).  Additionally, macrolides have properties that do not rely on drug concentration 
equilibrium between serum/plasma and tissue concentrations, such as permeation through 
nonporous membranes, pressure gradient bulk flow, and active transport that may account for 
macrolide behavior (Benchaoui et al., 2004).  
Tulathromycin has been shown to accumulate in leukocytes (primarily macrophages and 
neutrophils) in greater amounts than older macrolides (Evans, 2005).  In a study utilizing 
radio-labelled tulathromycin and erythromycin, tulathromycin demonstrated a 26-fold greater 
influx into and slower release from bovine neutrophils over erythromycin (Siegel et al., 
2004).   Neutrophil lysis that occurs at the site of infection provides for additional drug 
release in the area of greatest bacterial populations (Evans, 2005).   
Pharmacokinetic and pharmacodynamic analysis 
Pharmacokinetics (PK) is the study of drug behavior in vivo, and is based on drug 
concentrations in body spaces over time (Bauer, 2004; Gabrielsson & Weiner, 2000).  
Measured parameters are based both on the properties of the drug and on the biological 
system in which the drug is studied (Bauer, 2004; Rescigno, 2010).  Pharmacokinetic 
behavior is broadly divided into absorption, distribution, metabolism/biotransformation, and 
excretion (Gabrielsson & Weiner, 2000; Goodman & Gilman, 2006).  Absorption is 
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considered complete for drugs administered intravenously (IV) but must be determined for 
those administered by other routes (intramuscular, subcutaneous, oral).  It determines the 
bioavailability (F), the percentage of drug that will reach the intended destination which is 
generally the blood stream.  Distribution measures the amount of drug that is dispersed from 
the central compartment (blood) into intracellular and interstitial fluid.  Highly vascular 
tissues have enhanced perfusion, facilitating drug exposure particularly by compounds with 
high lipid solubility.  The purpose of drug metabolism generally is to increase the water 
solubility of the compound in preparation for excretion, which is largely accomplished via 
renal or enterohepatic action (Goodman & Gilman, 2006).     
Physiochemical traits of a drug such as size, lipid solubility, degree of ionization, and 
protein binding properties determine how it will traverse cell membranes and arrive at a 
target location, how it will persist at that location, and how it will be removed from that 
location (Goodman & Gilman, 2006).  The goal of clinical PK is to use calculated parameters 
of the drug’s behavior in the body to maximize therapeutic benefits while minimizing toxic 
side effects (Bauer, 2004; Goodman & Gilman, 2006).   
Pharmacokinetic analysis is used to estimate parameters that characterize the behavior of 
a drug and can be done experimentally or through the use of modeling (Bauer, 2004).  
Pharmacokinetic modeling attempts to match drug behavior with mathematical equations that 
can be used to predict drug activity in other populations, with the ultimate goal of 
maximizing therapeutic benefits while minimizing the chance of adverse effects from a given 
medication (Bauer, 2004).  Pharmacokinetic models that describe the behaviour of one drug 
may also be applied to estimate behavior of compounds with similar structures or 
16 
 
 
 
physiochemical properties (Resigno, 2003).  Optimal models are retrodictive, agreeing with 
data from the experiment on which they are based; are predictive, correctly estimating what 
will be seen in future experiments; and are understood, so that the model fits in logically to 
what has been seen in other experiments (Rescigno, 2003).   
Non-compartmental PK models of experimental results consider the entire body as a 
single “vessel” into which the drug is administered and from which the drug is removed; 
analysis using this model is referred to as NCA (Bauer, 2004; Gabrielsson & Weiner, 2000; 
Goodman & Gilman, 2006; Rescigno, 2003).  These models make the fewest assumptions 
about how the drug is distributed without the need to describe movement from one location 
to another (Gabrielsson & Weiner, 2000).  Several fundamental parameters are critical to 
establishing valid models from which other parameters can be determined (Bauer, 2004; 
Gabrielsson & Weiner, 2000; Rescigno, 2003).  Clearance (CL), the amount of drug removed 
per unit of time, is the most important parameter to determine since it dictates the dose and 
frequency of drug administration needed to reach a steady-state concentration (Bauer, 2004; 
Goodman & Gilman, 2006).  This parameter indicates how efficiently the body removes the 
specific drug and provides information on the balance needed between administration and 
elimination to keep drug levels within the therapeutic index.  CL encompasses perfusion, 
diffusion, filtration, metabolism, and transport processes for the specific drug (Gabrielsson & 
Weiner, 2000).  The volume of distribution (Vd) dictates how broadly the drug mobilizes 
throughout the body and is proportional to the amount of drug in the body; Vd is generally 
small if most of the drug is retained in the blood stream and large if the drug disseminates to 
tissues (Bauer, 2004; Gabrielsson & Weiner, 2000; Goodman &; Gilman, 2006).  When the 
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route of administration is anything other than IV, bioavailability (F) will have an influence 
on these parameters; consequently, they become apparent clearance (CL/F) and apparent 
volume of distribution (Vd/F).   
Other pharmacokinetic parameters are measured or calculated from these primary factors.  
Graphical representations of drug concentrations over time are used to calculate the area 
under the time-concentration curve (AUC), which gives an estimation of total drug exposure 
(Bauer, 2004; Gabrielsson & Weiner, 2000).  NCA calculation of this parameter utilizes a 
sum of trapezoidal areas or non-linear regression; consequently, the more frequently 
measurements of drug concentration are collected, the smaller the magnitude of error in the 
calculation (Gabrielsson & Weiner, 2000; Rescigno, 2010).  Half-life (t½) is the time needed 
to remove half of the drug from the compartment under study (usually plasma but can also be 
applied to a specific tissue), and is dependent on both CL and Vd (Bauer, 2004; Gabrielsson 
& Weiner, 2000; Goodman & Gilman, 2006).  The elimination rate of a drug is estimated by 
the determining the terminal slope (λz) of the time-concentration curve; the maximum drug 
concentration (Cmax) and time to reach maximum drug concentration (Tmax) are derived 
directly from the time-drug concentration plot (Gabrielsson & Weiner, 2000; Goodman & 
Gilman, 2006; Rescigno, 2003).  
Compartmental analysis uses kinetic models to predict the time-concentration plot and 
considers drug entry and elimination from various segments of the body, such as blood, fat, 
or central nervous system (Gabrielsson& Weiner, 2000; Goodman & Gilman, 2006; 
Rescigno, 2010).  Experimental results of drug behavior may not agree with non-
compartmental models and more complex analysis that accounts for distribution and 
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redistribution of drugs from the central (blood stream) and peripheral (tissue) compartments 
may be required (Gabrielsson & Weiner, 2000).  Additional parameters are utilized to 
describe how the drug moves through the body.  Elimination is divided into two different 
phases described by the initial and terminal slopes and may more accurately describe the 
drug concentration at a particular time than NCA (Gabrielsson & Weiner, 2000; Rescigno, 
2003).  Model building is multifaceted utilizing multiple exponential terms and complex 
calculations which are made possible through the use of specialized computer programs.  
Once a model is complete, it is evaluated for precision and agreement with experimental 
results collected from additional studies (Bauer, 2004; Rescigno, 2003).   
Information about pharmacokinetic parameters such as clearance and effective dose can 
be used to predict drug behavior in another species or with an alternative route of 
administration (Gabrielsson & Weiner, 2000).  Allometric scaling has been used to 
extrapolate drug behavior in different species, utilizing a PK assessment of a drug in one 
species and physiologic properties of body size and metabolism in the alternate species to 
estimate drug behavior in the alternate species (Drew et al., 2004).  More recently, 
physiologically-based pharmacokinetic (PBPK) models have been developed to more 
accurately evaluate drug behavior in vivo.  These highly complex models involve multi-
compartment analysis and can be used to predict drug disposition into and out of individual 
tissues (Gabrielsson & Weiner, 2000).  PBPK models permit extrapolation of drug effects 
(both therapeutic and toxicological) between species and can be used to perform risk 
assessments from drug exposure to alternate species (Sweeney et al., 2009).  Additionally, 
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they can be used to evaluate specific tissues such as skin or nasal mucosa that might not be 
easily incorporated into less complex models (Norman et al., 2010; Sweeney, 2009). 
Pharmacodynamics (PD) is the study of the relationship between drug exposure, 
mechanism of action, and the biological effects of the drug on the host or in the case of an 
antibiotic, on the bacterial target (Gabrielsson & Weiner, 2000; Rescigno, 2010).  While PK 
evaluates the concentration of a drug over time, PD focuses on the effects of the drug over a 
range of concentrations.  Parameters used to evaluate PD effects of a drug include the 
minimum inhibitory concentration (MIC) against a specific bacterium in vitro, post-antibiotic 
effects (PAE), and kinetics of bacterial killing (Godinho et al., 2005; Wise, 2001).  Drugs 
that demonstrate PAE maintain antibacterial activity for a period of time beyond when the 
drug concentration falls below the MIC for a specific pathogen (Wise, 2001).  The 
relationship between drug concentration and effect is complex in biological systems; 
however, controlled in vitro PD experiments contribute to the development of mathematical 
descriptions of drug activity (Rescigno, 2003).    
The two model descriptors can be combined to provide PK/PD assessment of a drug and 
its intended activity.  Antibiotics are traditionally classified into one of three categories, time-
dependent, concentration-dependent, and time-dependent with a post-antibiotic effect, based 
on PK/PD activity (McKellar et al., 2004).  The activity of time-dependent antimicrobials 
relies on the length of time that drug levels are at or above the MIC (T>MIC) of the specific 
pathogen being treated; the longer drug levels persist above the MIC, the more effective the 
antibiotic treatment.  Common time-dependent antibiotics include penicillins, 
cephalosporins, and older macrolides (Van Bambeke & Tulkens, 2001).  Concentration-
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dependent antimicrobials rely on the maximum level of antimicrobial above the MIC 
(Cmax/MIC) of the pathogen being treated and frequently demonstrate PAE; effective 
treatment is based upon maximizing plasma or tissue concentrations of the drug and benefits 
from the suppression of bacterial growth that continues for a period of time even after drug 
levels fall below the MIC.  Aminoglycosides, tetracyclines, and fluoroquinolones are 
members of this category (Van Bambeke & Tulkens, 2001).  The third category of 
antibiotics, which includes streptogramins, ketolides, and newer macrolides, has 
characteristics of both, with time-dependent killing mechanisms and PAE.  PAE is based on 
the concentration of drug, the time that bacteria are in contact with the drug, and/ or its 
mechanism of action (Van Bambeke & Tulkens, 2001).  Total drug exposure is evaluated by 
the area under the time-concentration curve (AUC) and represents a mathematical summation 
of drug concentrations in the compartment being assessed (Van Bambeke & Tulkens, 2001; 
Gabrielsson & Weiner, 2000).  The AUC/MIC ratio is frequently used to determine drug 
efficacy of this group (Van Bambeke & Tulkens, 2001; Li & Zhu, 2002).  PAE may be due 
to the effects of altered DNA or protein synthesis (Li & Zhu, 2002).   
Effects of drug exposure on a bacterial species are important aspects of determining 
potential drug efficacy.  Minimum inhibitory concentration (MIC) determination involves 
incubating a bacterial suspension with a range of doubling antibiotic concentrations for a 
specified time and examining them for growth inhibition;  MIC’s are considered the “gold 
standard” of susceptibility testing (Andrews, 2001; Catry et al., 2007).  The MIC is defined 
as the lowest concentration of antimicrobial that suppresses bacterial growth in a defined 
incubation period (Andrews, 2001).  The Clinical and Laboratory Standards Institute 
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(formerly the National Committee for Clinical Laboratory Standards) establishes interpretive 
criteria for “susceptible,” “intermediate,” or “resistant” determinations between the bacterial 
isolate and the drug (Clinical and Laboratory Standards Institute, 2008).    
Mean bactericidal concentrations (MBC) can be identified by sub-culturing the bacterial-
antibiotic suspension used in MIC testing onto antibiotic-free media to determine what 
concentration of antibiotic is required for complete bacterial killing (Andrews, 2001).   
Bactericidal antibiotics have MBC that are very close to MIC values since their mode of 
action results in irreversible damage to the bacterium; bacteriostatic drugs have MBC that are 
much greater than MIC (Andrews, 2001).  Kill-kinetic assays are an established method to 
determine the degree of bacterial killing (Firsov et al., 1997; Stratton et al., 1987).  In this 
testing method, a growing bacterial suspension is incubated with a known concentration of 
antibiotic and serially tested to establish the drug concentration and time needed to achieve a 
defined level of bacterial death (Firsov et al., 1997; Stratton et al., 1987).  The most common 
chosen levels of killing are MBC90 (90 % killed), MBC95 (95% killed), and MBC99 (99% 
killed). 
Drug elimination is also a critical component of in vitro behavior, particularly in food 
animal species from which products are expected to enter the human food chain.  
Tulathromycin is manufactured as a single isomer or parent compound, designated CP-
472,295(e).  This molecule equilibrates in solution into in 9:1 mixture of two tulathromycin 
isoforms, designated CP-472,295 and 547,272, respectively (Gáler et al., 2004).  The 
common fragment or marker residue for these two different isoforms is CP-60,300 (Gáler et 
al., 2004).  Two different methods for tulathromycin detection have been described for 
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different biological matricies.  Since tissue residues in food animal species are used to 
establish adequate withdrawal periods after drug administration, detection protocols that 
identify drug compounds in these tissues must receive regulatory approval.  Frequently these 
methods are designed to meet stringent guidelines that maximize detection of the drug in any 
form.  Tissue residue studies are therefore conducted utilizing a FDA-approved methodology 
detecting the common fragment CP-60,300.   
Determination of tissue concentrations is a necessary method of evaluating certain drugs 
for efficacy, particularly macrolide antimicrobials.  An accurate, precise, and robust detection 
method is needed to characterize a drug’s distribution in the animal and its relationship to 
efficacy (Gáler et al., 2004).  A detection method that focuses on the most active structure of 
the drug being evaluated provides more information on the potential therapeutic potential of 
the specific medication than overall tissue concentrations.  The method described by Gáler et 
al (2004) focuses on the evaluation of the parent compound of tulathromycin (CP-
472,295[e]) in lung tissues and plasma since these matricies are critical to determining 
potential drug efficacy in the tissue(s) being targeted for therapy. 
Bacterial pneumonia 
 Bacterial respiratory disease is a common health concern in small ruminants with 
potential life-threatening consequences (Ackermann & Brogden, 2000; Berge et al., 2006; 
Brogden et al., 1998; Martin, 2010; Washburn et al., 2007; Yener et al., 2009).  The most 
frequently implicated bacterial agents in this disease complex are Mannheimia haemolytica, 
Pasteurella multocida, and Bibersteinia (Pasteurella) trehalosi, often complicated by 
Mycoplasma species (Ackermann & Brogden, 2000; Alley et al., 1999; Berge et al., 2006; 
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Brogden et al., 1998; Cutlip et al., 1998; Rahman & Singh, 1990; Shayegh et al., 2009; 
Washburn et al., 2007; Yener et al., 2009; Zamri-Saad & Mera, 2001).  B. trehalosi, 
previously classified as M. haemolytica type T but now identified as a distinct species, 
utilizes many of the same virulence mechanisms as M. haemolytica.  An antimicrobial shown 
to be effective against these pathogens would be highly useful in caprines. 
Pathogenesis of bacterial pneumonia in goats is similar to that seen in other livestock 
species.  Upper respiratory viruses such Parainfluenza 3 (PI-3), adenovirus type 6, respiratory 
syncytial virus (RSV), bovine adenovirus type 2, ovine adenovirus types 1, 2, and 5, caprine 
arthritis encephalitis virus, and reovirus type 1, as well as Mycoplasma bacteria have all been 
identified as agents capable of causing primary pneumonia in small ruminants (Brogden et 
al., 1998; Murphy et al., 2010; Purdy et al., 2003; Yener et al., 2005).  More importantly, 
these agents damage host defenses and predispose the lung to bacterial entry into lungs.  
Stress associated with weather extremes, weaning, transport, and poor nutrition have all been 
implicated as predisposing factors associated with the development of pneumonia (Brogden 
et al., 1998; Purdy et al., 2003; Shafarin et al., 2009).  M. haemolytica, P. multocida, and B. 
trehalosi are all commensals of the upper respiratory tract in ruminants that contribute to 
severe pneumonia upon reaching the lungs (Ackermann & Brogden, 2000; Autio et al., 2007; 
Confer, 2009; Rice et al., 2007; Ward et al., 2002; Whiteley et al., 1992; Yener et al., 2009).  
These commensal agents have been recovered from nasal and pharyngeal samples collected 
from goats, sheep, and cattle (Shiferaw et al., 2006; Tomassini et al., 2009).  Any conditions 
resulting in suppressed immunity can predispose the animal to entry of these agents into 
deeper lung tissue and the development of pneumonic pasteurellosis (Brogden et al., 1998; 
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Cutlip et al., 1996; Dassanayake et al., 2010; Ewers et al., 2006).  Additionally, neutralizing 
antibodies to bovine respiratory viruses have been documented in small ruminants, with 
Bovine Herpesvirus-1 (BHV-1) and PI-3 showing the highest seroprevalence rates in goats 
(Yeçilbag & Güngör, 2008).  The evidence of a serologic immune response in these animals 
indicates that these viruses are capable of contributing to upper respiratory mucosal damage 
and thus secondary bacterial entry into the lungs.  Co-localization of PI-3 and M. haemolytica 
identified by immunohistochemical (IHC) staining in association with fibrinous 
bronchopneumonia demonstrated by Yener et al (2005) may indicate that PI-3 has an 
important role in caprine pneumonia.  Goats are also frequently used as models for studying 
respiratory disease in cattle due to the similarity of these two species in susceptibility to 
inciting causes, bacterial pathogens, and mechanisms of pathology (Purdy et al., 1998). 
 The pathogenesis of the common respiratory diseases in cattle has been well described 
(Ackermann & Brogden, 2000; Angen et al., 2009; Autio et al., 2007; Confer, 2009); 
Czuprynski et al., 2004; Haines et al., 2004; Mosier, 1997;  Rice et al., 2007) and parallel 
disease development has been observed in goats.  Infection of upper and lower respiratory 
tissues by agents such as Bovine Herpes Virus 1 (BHV1), Bovine Viral Diarrhea Virus 
(BVDV), Parainfluenza 3 virus (PI3), and Bovine Respiratory Syncytial Virus (BRSV) result 
in damage to upper respiratory epithelium and local mucosal immunosuppression, facilitating 
lung infection by bacterial agents (Angen et al., 1999; Autio et al., 2007; Confer (2009); 
Czuprynski et al., 2004; Ewers et al., 2004; Fulton et al., 2009; Gagea et al., 2006; Hodgson 
et al., 2005; Rice et al., 2007).   Mycoplasma bovis has been shown to both predispose to and 
benefit from the presence of other respiratory pathogens in contributing to pulmonary lesions 
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(Nicholas & Ayling, 2003; Razin et al., 1998; Vanden Bush & Rosenbusch, 2003; Vanden 
Bush & Rosenbusch, 2004).  As is seen in goats, stress from weaning, weather extremes, 
transport, and comingling can contribute to depressed host immunity in cattle, predisposing 
to establishment of bacterial lung infection (Hodgson et al., 1996; Rice et al., 2007; Straus et 
al., 1998).    
Pneumonic agents are often found in combination within diseased tissues, providing 
evidence of the opportunistic activity of normal upper respiratory flora (Srikumaran et al., 
2007).  Infections by upper respiratory pathogens incite the release of pro-inflammatory 
cytokines IL-1, IL-8, TNF-α, and recruitment of phagocytic cells (Hodgson et al., 1996).  
Damage to upper respiratory defense mechanisms by viral agents includes breakdown of β-
defensins, anionic peptides and mucous secretions; decreased clearance by the mucociliary 
escalator; and aerosolization of pharyngeal microbiota; the result is bacterial aspiration and 
establishment of pulmonary infections (Ackermann & Brogden, 2000; Rice et al., 2007).   
Characteristic lesions of pneumonic pasteurellosis are similar in goats, cattle, and sheep 
and include an acute fibrinonecrotic pneumonia associated with infiltrates of neutrophils, 
fibrin, and proteinaceous fluid (Ackermann & Brogden, 2000; Fett et al., 2008; Purdy et al., 
2003; Yener et al., 2009; Zamri-Saad & Mera, 2001).  Shafarin et al. (2009) demonstrated 
these gross and histopathologic lesions in goats challenged with P. multocida.  Pneumonic 
goat lungs that were examined by immunohistochemistry (IHC) specific for M. haemolytica 
showed strongest staining in epithelial cells of small bronchioles and pneumocytes as well as 
in degenerating neutrophils and macrophage-like cells particularly in areas of necrosis 
(Yener et al., 2009).  Alveolar macrophages from goats challenged with M. haemolytica 
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showed depressed phagocytic activity compared with macrophages from goats challenged 
with other respiratory agents (Zamri-Saad & Mera, 2001).  The severe tissue damage seen 
with these bacterial pathogens demonstrates the need for effective antimicrobial therapy. 
Similarities and differences between goat and cattle production in the U.S. highlight 
diverse challenges associated with the epidemiology of bacterial pneumonia in goats.  Goats 
and cattle are subjected to many of the same stresses associated with increased susceptibility 
to clinical pneumonia, such as weaning, weather extremes, and nutritional deficiencies 
(Ackermann & Brogden, 2000; Brogden et al., 1998; Czuprynski et al., 2009; Hodgson et al., 
1996; Murphy et al., 2010; Purdy et al., 2003; Rice et al., 2007; Straus et al., 1998; Yener et 
al., 2005).  Susceptibility to upper respiratory agents, particularly BHV-1 and PI-3, has also 
been demonstrated in both species.  The similarities in resident pharyngeal flora facilitate 
exposure to opportunistic lung pathogens in both bovine and caprine species.  Several 
management practices associated with cattle production increase the risks for this disease 
complex, including co-mingling of animals from different sources at barns and auctions; 
intensive management associated with finishing in feedlots; and long-distance shipping to 
these feeding operations.  Most market goat feeding systems rely on pasture-based, extensive 
management, which decreases the risk for the spread of infectious agents associated with 
close contact in small pens.  Extensive management, however, does present different 
challenges such as less frequent monitoring for signs of disease development and the 
nutritional stresses associated with marginal forage systems.  In addition, a plethora of 
vaccines directed against upper and lower respiratory disease agents are labeled for use in 
cattle, and pre-conditioning programs are more widely implemented to bolster immunity 
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prior to contact with stressful events.  No such vaccines are available for use in goats and 
pre-conditioning, which is extremely difficult to accomplish in extensively managed 
operations, is a rare occurrence in caprines. 
Bacterial pneumonia agents 
M. haemolytica is a Gram negative coccobacillus in the Pasteurellaceae family.  It was 
originally classified into 16 serotypes based on surface antigens that reacted in an 
agglutination reaction (Biberstein, 1978).  A novel serotype, A17, was identified in sheep in 
1995 (Rice et al., 2007).  Further characterization divided the bacteria into 13 “A” biotypes, 
which ferment arabinose, and 4 “T” biotypes, which ferment trehalose (Blackhall et al., 
2007; Lo & Shewen, 1991).  Sequencing of 16S rRNA determined that these biotypes were 
actually distinct species; 12 of the A biotypes are currently assigned to M. haemolytica and 
one to M. glucosida while the four T biotypes are designated as B. (Pasteurella) trehalosi 
(Angen et al., 1999; Rice et al., 2007; Sneath & Stevens, 1990).     
M. haemolytica is considered the major pathogen in ruminant respiratory disease (Frank 
& Briggs, 1992; Rice et al., 2008).  Serotypes A1, A2, and more recently A6 are the most 
commonly recovered serotypes colonizing the nasopharynx of cattle, sheep, and goats, with 
other serotypes being identified infrequently (Fett et al., 2008; Frank & Briggs, 1992; Frank 
& Smith, 1983; Jaramillo-Arango et al., 2008; Rice et al., 2008).  Clinical pneumonia is most 
frequently caused by serotype A1 in cattle while in small ruminants A2 is the main identified 
serotype (Dassanayake et al., 2009; Highlander, 2001; Odugbo et al., 2004; Rice et al., 
2008).  A review of isolates from clinical lesions in goats found that serotype A2 represented 
92% of all M. haemolytica isolates identified (Fodor et al., 1999).  M. haemolytica and B. 
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trehalosi have been isolated from pharyngeal swabs of healthy goats, indicating that 
opportunistic entry into lung tissue is possible in goats (Ward et al., 2002).   
M. haemolytica causes severe fibrinonecrotic pneumonia in ruminants but not in other 
species (Ackermann & Brogden, 2000; Deshpande et al., 2002; Zecchinon et al., 2004).  The 
two main virulence factors associated with this pathogen are lipopolysaccharide (LPS), 
which is common in infections with all Gram negative bacteria, and a secreted leukotoxin 
(Lkt) that primarily targets ruminant leukocytes  (Atapattu & Czuprynski, 2007; Baluyut et 
al., 1981; Clinkenbeard et al., 1989; Dassanayake et al., 2007a; Dassanayake et al., 2007b; 
McClenahan et al., 2008; Sacco et al., 2006).  LPS can produce cytotoxicicity and apoptosis 
in bovine endothelial cells (McClenahan et al., 2008; Paulsen et al., 1989).  Additionally, 
LPS binds to and stabilizes Lkt, preventing its degradation and augmenting its activity 
(Jeyaseelan et al., 2002).   Lkt, a calcium-dependent cytotoxin, is a member of the RTX 
family of toxins produced by many Gram negative bacteria (Atapattu & Czuprynski, 2007; 
Baluyut et al., 1981; Clinkenbeard et al., 1989; Dassanayake et al., 2007a; Dassanayake et 
al., 2008; Deshpande et al., 2002; Zecchinon et al., 2004; Zecchinon et al., 2005).  Lkt 
activity is responsible for much of the gross and histopathologic tissue damage seen with M. 
haemolytica and B. trehalosi infections (Clinkenbeard et al., 1989; Dassanayake et al., 
2007b; Jeyaseelan et al., 2002; Leite et al., 2005; Zecchinon et al., 2005).  Species 
susceptibility to this bacterial pathogen may be characterized by the ability of Lkt to activate 
leukocytes in cattle, sheep, and goats but not in other species (Dassanayake, et al., 2007a ; 
Dassanayake et al., 2007b ; Fett et al., 2008 ; Lawrence et al., 2007 ; Lawrence et al., 2008 ; 
Zecchinon et al., 2005). 
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As more microbiologists have differentiated M. haemolytica from B. trehalosi through 
the use of specific biochemical or molecular testing, the importance of B. trehalosi as a 
pathogen in sheep and goats is increasingly recognized.  Leukotoxin-producing strains of B. 
trehalosi have been associated with clinical pneumonia in sheep (Dassanayake et al., 2010).  
Dassanayake et al. (2010)  identified that B. trehalosi has a shorter doubling time and reaches 
a 3-log higher cell density after 5 hours of incubation in vitro than M. haemolytica.   B. 
trehalosi is able to inhibit growth of M. haemolytica in an as yet uncharacterized, contact-
dependent mechanism, indicating that it may have greater pathogenic potential than 
previously documented (Dassanayake et al., 2010). 
While the pathogenic processes associated with M. haemolytica appear to be limited to 
ruminants, clinical conditions related to P. multocida infections have been identified in a 
range of species, including swine, dogs, rabbits, and chickens (Davies et al., 2003; 
Ogunnariwo & Schryvers, 2001; Weber et al., 2004). This pathogen is most frequently 
identified with primary respiratory disease in goats, although rarely hemorrhagic septicemia 
has been reported (Ewers et al., 2004; Shafarin et al., 2009).    
P. multocida is a highly heterogeneous species with four recognized subspecies:  
multocida, gallicida, septica, and tigris (Shayegh et al., 2009).  Additionally, there are five 
identified “capsular types” (A, B, D, E, and F) with differing antigenic specificities (Dabo et 
al., 2007; Shayegh et al., 2009).  Type A is the most common capsule types recovered from 
goat lesions although occasionally Type D has been reported (Ewers et al., 2006; Shayegh et 
al., 2009).  Strains of P. multocida that are positive for the toxA gene express a 
dermonecrotic toxin that activates intracellular signalling cascades, producing severe tissue 
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damage, endothelial leakage, and cell lysis (Ewers et al., 2006; Shayegh et al., 2009; Wilson 
& Ho, 2004).  Additional virulence factors include two transferring binding proteins encoded 
by tbpA and tbpB; a filamentous hemagglutinin encoded by pfhA; and a tight-adherence 
factor that thwarts host immune response and is up-regulated in the presence of commonly 
prescribed antibiotics (Melnikow et al., 2008; Shafarin et al., 2007; Shayegh et al., 2009).  
Lesions associated with P. multocida pneumonia include acute to subacute 
bronchopneumonia with occasional pleuritis (Dabo et al., 2007; Shafarin et al., 2007). 
Various species of Mycoplasma can cause and contribute to respiratory disease in goats, 
including M. ovipneumonia, M. capricolum, M. mycoides Large Colony, M. mycoidies ssp. 
capri, M. putrifaciens, and M. arginini (Orós et al., 1997; Rodríguez et al., 1996).  M. 
capricolum ssp. capripneumoniae causes caprine progressive pleuropneumonia and can 
result in widespread outbreaks with severe economic consequences (Chazel et al., 2010).  
Pneumonia and pleuritis have been associated with M. ovipneumoniae in goats; however, this 
agent has also been isolated from the upper respiratory tract of clinically normal goats, 
indicating that it may act as an opportunist to gain entry into the lungs (Goltz et al., 1986).  
Mycoplasma in sheep and goats can be seen in conjunction with other respiratory bacteria, 
particularly M. haemolytica and P. multocida (Gonçalves et al., 2010; Oros et al., 1997).  In 
a challenge study in bighorn sheep involving a combination of M. ovipneumoniae and M. 
haemolytica, three of four dual-challenged animals developed fatal pneumonia 1-5 days post-
challenge.  The remaining animal died of pneumonia before challenge with M. haemolytica 
but its lungs were culture-positive for both M. ovipneumoniae and M. haemolytica; an 
identical strain of M. haemolytica was identified from the nasopharynx, signifying that 
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resident or introduced M. haemolytica can benefit from the presence of M. ovipneumoniae in 
establishing respiratory infections (Dassanayake, 2010).     
Characteristics of this genus include small size, lack of a cell wall, and a highly variable 
surface protein structure that facilitates evasion of host immune responses and persistence in 
affected animals (Caswell & Archambault, 2007; Razin et al, 1998; Vanden Bush & 
Rosenbusch, 2003).  Genomes encode for a family of highly antigenic variable surface 
proteins (VSP’s); these genes undergo high rates of recombination which results in altered 
antigenic presentation, immune evasion, and persistence in the host (Caswell & Archambault, 
2007; Razin et al., 1998; Vanden Bush & Rosenbusch, 2004).  Pathologic lesions include 
subacute suppurative bronchiolitis, alveolitis, pleuritis, bronchopneumonia, fibrinonecrotic 
pleuropneumonia, and dilation of interlobular septa (Goltz et al., 1986; Rodríguez et al., 
1996).   
Meeting FDA Requirements 
Safety 
The purpose of drug safety studies is to determine if any undesirable side effects if any 
can be attributed to administration of the drug to the target species.  The therapeutic index 
(TI) of a compound is defined as the ratio of the lethal dose in 50% of the population 
compared to the minimum effective dose in 50% of the population and provides an indication 
of the relative safety of that drug (Burns, 1999).  Drugs with larger TI have a wider margin of 
safety since the dose associated with death is much greater than the dose needed to achieve 
effective therapy (Burns, 1999).  To assess target animal safety, the effective dose and 
progressively higher doses are administered for an extended duration to elicit detrimental 
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effects in test subjects.  A variety of assessments are used to evaluate these effects including 
physical, physiologic, and tissue parameters.  Additionally, the target population is selected 
to represent the animals most likely to demonstrate harmful outcomes if any occur.   
One study has been reported that assesses the safety of tulathromycin administration in 
goats (Washburn et al., 2007).  Adult goats in this study were injected with 25 mg/kg which 
is ten times the label dose (2.5 mg/kg) for cattle and swine and observed for signs of adverse 
reactions.  Observations on physical condition (survival, general attitude, fecal consistency, 
appetite, and injection site lesions); clinical pathology parameters (complete blood count, 
serum chemistry, and urinalysis); and genotoxicity assessment using flow cytometry-
measured DNA content as a measure of chromosomal abnormalities associated with 
tulathromycin exposure were conducted for seven days following drug administration.  The 
only parameters found to be significantly different between treatment and control animals 
were heart rate (P = 0.04) and creatine kinase  (P = 0.001).  Studies designed to meet FDA 
standards generally require extensive outcome assessments including gross and 
histopathologic tissue evaluations in addition to ante mortem appraisals described in this 
study. 
Human Food Safety 
A highly sensitive and specific detection method is needed to ensure accurate 
determinations of drug concentrations in plasma and tissues (Gáler et al., 2004).  To meet 
FDA requirements for drug residue analysis, a method must maximize sensitivity and 
accuracy in detecting the compound.  The method that identifies a common fragment of the 
various forms of tulathromycin (CP-60,300) was designed by Pfizer Animal Health and 
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approved as the residue detection method by the FDA CVM.  The inclusion of samples that 
have been spiked with known tulathromycin concentrations along with analysis of incurred 
tissues from treated animals helps to minimize any analytical bias in that may occur from 
using only one sample type (Gáler et al., 2004).  To utilize this procedure on goat tissues, the 
method must be validated using goat tissue samples spiked with known concentrations of 
tulathromycin; incurred tissues from tulathromycin-treated goats; and tissues from untreated 
goats.  Validation involves assessment of several parameters including specificity, linearity, 
recovery, accuracy, precision, limit of detection (LOD), limit of quantitation (LOQ), and 
stability of the extracts.   Furthermore, the method needs to be bridged to at least one of the 
species evaluated in the FDA-approved method.   
Once the method is validated, it can be used to determine concentrations of the common 
fragment or marker residue CP-60,300 in tissues from market age animals that would be 
most likely to enter the human food supply.  Animals are injected with the proposed label 
dose and tissues are collected and analyzed for tulathromycin content at various time points 
following injection.  This data can then be used by the FDA to establish an adequate 
withdrawal period in the target species. 
Efficacy 
In order to meet the standards that FDA requires for antimicrobial approval, the drug 
must be shown to be effective in the species under study.  This can be accomplished by more 
than one method.  Ideally one would utilize the compound in natural outbreaks of bacterial 
disease since challenge studies with pathogenic organisms may not completely mimic what is 
seen in field conditions.  Due to the intensive nature of cattle and swine production in the 
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U.S., efficacy studies in these species could be conducted under Good Clinical Practice 
(GCP) conditions utilizing tulathromycin compared to an alternative antimicrobial regimen to 
treat naturally occurring bacterial pneumonia.  Many studies have been published that 
evaluate the efficacy of tulathromycin in the treatment of cattle and swine pneumonia 
(Booker et al., 2007; Evans, 2005; Godinho et al., 2005; Hart et al., 2006; Kilgore et al., 
2005; Nickell et al., 2008; Perrett et al., 2008; Schunicht et al., 2007; Van Donkersgoed et 
al., 2008; Wellman & O'Connor, 2007).   
Goat production is more extensive than that used in cattle and swine, with very few 
operations that raise large numbers of goats in small areas (Glimp, 1995).  Requirements for 
adherence to GCP standards and treatment of naturally occurring pneumonia would be 
difficult if not impossible to accomplish in a defined time period in these production systems; 
therefore, an alternative method based on pharmacokinetics in the target species along with 
assessments of bacterial susceptibility was selected to assess tulathromycin efficacy in 
caprines. 
To assess efficacy in cattle and swine, PK studies of tulathromycin behavior were 
conducted in addition to studies utilizing tulathromycin treatment in cases of naturally 
occurring clinical disease (Benchaoui et al., 2004; Nowakowski et al., 2004).  A PK study 
conducted in goats to evaluate drug absorption and distribution as well as to perform PK 
analysis would provide valuable data that may help to establish efficacy.  Additionally, lung 
tissue analysis for the parent compound of tulathromycin (CP-472,295[e]) can further define 
lung concentrations of this drug.  While examination of lung tissue homogenates is not a 
definitive method for detecting drug concentrations of extra-cellular fluid, this analysis does 
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provide insight into the PK/PD behavior of drugs for which serum and plasma data are not 
useful (Benchaoui et al., 2004).  In the case of long acting macrolides such as tulathromycin, 
PK/PD assessments based on lung tissue concentrations correlate better with total drug 
exposure and clinical efficacy than PK/PD assessments made on blood (Benchaoui et al., 
2004).  Results of PK behavior of tulathromycin in goats could then be compared to that 
found in cattle and swine.  Profiles obtained from the PK study could also permit calculation 
of the AUC, an indication of total drug exposure, from both plasma and tissue compartments. 
In vitro investigations into the effects of tulathromycin on respiratory bacterial pathogens 
can indicate the potential efficacy of this drug against caprine respiratory pathogens.  
Although goats and cattle share susceptibility to many of the same bacterial agents, 
differences in serotype, capsular type, and species (in the case of Mycoplasma) of recovered 
bacteria have been identified.  Utilizing a collection of bacterial isolates that have been 
cultured from lung lesions in goats that have succumbed to clinical pneumonia would be a 
more effective way to assess tulathromycin efficacy against these pathogens.  Evaluation of 
MIC, MBC, and killing ability through kinetic-kill assays can provide valuable insight into 
the true antibacterial activity of tulathromycin.  Kinetic assays in particular can demonstrate 
bactericidal activities of the drug being evaluated (Dorfman, 2008).  Employing the MIC 
values determined in these evaluations in the calculation of the AUC/MIC ratio will provide 
an effective means of assessing tulathromycin efficacy that has been shown to be useful with 
other new macrolides (Amsden, 2001). 
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Figure 1.1 Pharmacokinetic/pharmacodynamic parameters used to predict efficacy of 
antimicrobials against specific bacterial pathogens.  From “PK/PD approach to antibiotic 
therapy review”, Rxkinetics software (www.rxkinetics.com/antibiotic_pk_pd.html, 8-16-
10) 
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Figure .2.  Structure of the two isomers of tulathromycin that exist in a 9:1 (A:B) ratio under 
physiologic conditions.  From Evans, N.A. (2005) Tulathromycin: an overview of a new 
triamilide antibiotic for livestock respiratory disease. Veterinary Therapeutics, 6, 83-95. 
 
 
 
 
 
 
 
 
 
48 
 
 
 
CHAPTER 2.  SAFETY EVALUATION OF TULATHROMYCIN USE 
IN THE CAPRINE SPECIES 
 
Adapted from the manuscript published in the Journal of Veterinary Pharmacology and 
Therapeutics 
 
Kristin A. Clothier, DVM; Dianna M. Jordan, DVM, MS, PhD; Alan T. Loynachan, 
DVM, PhD, DACVP; Ronald W. Griffith, DVM, MS, PhD, DACVM 
 
Abstract 
Antimicrobials available to treat bacterial respiratory disease in goats are extremely limited. 
Currently only cephalosporins have been approved for use in this species.  Concerns over 
antimicrobial resistance in human bacterial isolates have led to proposed restrictions on the 
use of this drug in food producing animals.  Tulathromycin is a triamilide macrolide 
antibiotic labelled for use against respiratory pathogens in cattle and swine.  The present 
study was conducted to evaluate the safety of tulathromycin in caprines using the youngest 
goats likely to be treated for respiratory disease.  Twelve male and 12 female, one week old, 
mixed-breed goats were statistically blocked by age and sex and assigned to receive either 
saline or tulathromycin at 1X, 3X, or 5X the recommended label dose for three times the 
normal duration.  Goats were injected once per week for three weeks and necropsied one 
week following the third injection.  No significant differences in physical parameters, feed 
intake, growth, clinical pathology measurements, or tissue (gross or histopathologic) 
assessments between treatment and control animals were identified that were associated with 
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tulathromycin administration.  Results of this study indicate that tulathromycin would be a 
safe antimicrobial when used at the recommended label dose in caprines. 
Introduction 
Bacterial pneumonia is a common and often life-threatening respiratory problem in both meat 
and dairy goats (Washburn et al., 2007; Yener et al., 2009).  Pasteurella multocida and 
Mannheimia haemolytica, often complicated by Mycoplasma species colonization, are the 
most common causes of respiratory infections in sheep and goats (Berge et al., 2006; 
Brogden et al., 1998; Washburn et al., 2007; Yener et al., 2009; Zamri-Saad & Mera, 2001).  
Options for approved antibiotic therapy to combat bacterial infections in caprines are 
severely limited and often must be administered in an off-label manner (Berge et al., 2006).  
The cephalosporin ceftiofur is the only antibiotic approved for use in goats (Fajt, 2001; Fajt, 
2003; Washburn et al., 2007; Webb et al., 2004).  Concern about antimicrobial resistance in 
human bacterial isolates and its association with cephalosporin administration to food 
animals has led to proposed limitations for extralabel cephalosporin use (Nolan, 2009).  In 
addition, antimicrobials used successfully in other ruminant species available for extra-label 
administration under a valid veterinary-client-patient relationship may be unsuitable for 
goats.  Tilmicosin, a macrolide antibiotic effective against respiratory pathogens when used 
in cattle and in sheep over 15kg, is cardiotoxic and potentially lethal in goats 
(Christodoulopoulos et al., 2002). 
Tulathromycin is a novel triamilide antibiotic in the macrolide class shown to be  safe 
and efficacious in treating respiratory disease in cattle and swine (Evans, 2005; Hart et al., 
2006; Nowakowski et al., 2004).  The objective of this study was to evaluate the safety of 
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tulathromycin in caprines using the youngest goats that would likely be treated for 
respiratory disease.  The hypothesis was that there are no toxic effects in goats associated 
with tulathromycin treatment. 
Materials and methods 
Twelve male and 12 female mixed-breed (dairy and meat) goats, one to seven days of age 
weighing 3.6-7.3 kg, were enrolled in this study.  Goats were identified by ear tag, housed 
individually in a climate-controlled facility, and fed a commercial, non-medicated milk replacer 
free choice.  Animals were acclimated for nine days prior to initial injections and received no 
pre-treatment medications or vaccinations.  All phases of the study were approved by the 
Institutional Animal Care and Use Committee of Iowa State University. 
Daily physical exams and twice-daily clinical evaluations were performed on all animals 
from day -9 to day 21.  Attitude, feed consumption, body temperature, heart rate, respiratory 
rate and fecal consistency were recorded.  Pre-treatment blood, urine and fecal specimens 
were collected on day -2 to assess general health and obtain baseline clinical pathology data.  
Clinical pathology assessments were repeated on days 11 and 21.   
Goats were statistically blocked by weight and sex and randomly assigned to treatment 
groups.  Group 1 goats were control animals injected subcutaneously with 0.9% sodium 
chloride (Hospira, Inc., Lake Forest, Il).  Groups 2, 3, and 4 goats were injected 
subcutaneously with   2.5-,7.5- or 12.5 mg/kg tulathromycin (Pfizer Animal Health, NY, 
NY), respectively, based upon body weights obtained the morning before dosing.  Doses 
were equivalent to 1X, 3X, or 5X, of the label dose of tulathromycin approved for cattle.  
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Animals received one injection per week for three treatments (three times the recommended 
duration) at different predetermined locations on the neck.  
On day 21 animals were weighed, euthanized by administration of IV xylazine to achieve 
general anesthesia and IV potassium chloride to induce cardiac arrest, and necropsied.  Tissues 
were evaluated for gross and histopathologic changes that could be related to tulathromycin 
administration.  Examined tissues included abomasum, adrenal glands, aorta, brain, cerebrum, 
thalamus, cerebellum, medulla oblongata, cecum, colon, duodenum, epididymis, esophagus, eyes 
(with optic nerve), gallbladder, heart (right atria, right ventricle, left atria, left ventricle), ileum, 
injection sites, jejunum, kidneys, liver (medial and left lobes), lung (peripheral tissue and large 
bronchus), mandibular, mediastinal, mesenteric lymph nodes,  mammary gland, 
semimembranosus muscle, omasum, pancreas, sciatic nerve, pituitary, prostate, rectum, 
reticulum, rumen, salivary gland, spinal cord (cervical, thoracic, and lumbar sections), spleen, 
testes, ovaries, thymus, thyroid gland/parathyroid, urethra, urinary bladder, and uterus.  Adrenal 
glands, brain, liver, kidneys, spleen, thyroid, thymus, and heart were weighed to ascertain organ 
to body weight ratios.   
Blinding was maintained such that no person having knowledge of the dosing was 
involved in the clinical evaluations, necropsies or histopathologic exams.  Quality assurance 
was provided in accordance with Good Laboratory Practices (GLP) (21 CFR Part 58) and 
was monitored by a Food and Drug Administration (FDA) representative to ensure adherence 
to GLP standards and the approved protocol. 
Statistical evaluations of two- and three-way interactions (treatment-by-time, treatment-by-
sex, and treatment-by-sex-by-time) at the 0.05 level of significance as well as main (treatment) 
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effects at the 0.10 level of significance (to meet FDA protocol specifications evaluating effects 
of tulathromycin administration) were performed using SAS statistical software (version 9.1, 
SAS Institute, Inc., Cari, NC).  Baseline parameter information from the acclimation period was 
used as the covariate where applicable, and autoregressive covariate structure was used.  Daily 
measurements of food consumption, body temperature, respiratory rate, and pulse rate were used 
to determined weekly means for statistical assessment.  These weekly means, weekly body 
weights, and clinical pathology results were used in repeated measure analysis.  Descriptive 
statistics were used to assess changes in gross and histopathologic tissue evaluations.  Organ 
weights to body weight ratio comparisons were made using continuous variable analysis.   
Results 
Results of statistical comparison methods and results for physical and clinical pathology 
parameters are listed in Table 2.1; results of tissue assessments are listed in Table 2.2.  All 
goats remained alert and responsive throughout the study.  None of the signs of discomfort 
associated with tulathromycin injection described in cattle (head shaking, pawing) were 
identified in the goats following any of the injections, possibly due to lower injection 
volumes in these smaller juvenile study subjects.  Two of the 5X goats vocalized briefly 
following injection and four goats (representing all treatment groups) had mild soft-tissue 
swelling at the injection site that resolved within 24-48 hours. 
All groups had a slight decrease in mean feed intake during the week following the initial 
injection but mean consumption rebounded over the following weeks for all groups.  Mean 
weekly feed consumption was lower for control goats (32.6 oz.) than for any of the treated 
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animals (34.5-36.3 oz.).  All groups of goats gained weight over the course of the study.  
Heart rate and respiratory rates increased in all groups during the study.   
PT and APTT were significantly different between treatment groups.  Values were 
highest for control goats (mean PT 14.1 seconds, mean APTT 40.6 seconds; treatment goat 
mean PT 12.9 seconds, mean APTT 20.8 seconds) and differences were not attributed to 
tulathromycin treatment.  Clotting profile normal ranges are not readily available for juvenile 
goats.  All groups had PT levels higher than those considered normal for adult caprines but 
APTT levels were within normal limits for goats. 
Treatment groups showed a significant difference in mean calcium level (10.1-10.9 
mg/dl) from control animals (9.7-10.2 mg/dl), although all calcium values were within 
normal limits.  Mean alkaline phosphatase levels were significantly higher (at P < 0.05) in 
the 1X (658.8 IU/L) and 3X (642.2 IU/L) groups than the control (419.4 IU/L) and 5X (456.7 
IU/L) goats and not attributed to tulathromycin administration.  Mean CK values were 
significantly different in the 5X (334.2 IU/L) group at the last measurement (after the third 
injection) from the other groups (187.0-246.0 IU/L); this variation may be associated with 
tissue irritation from larger drug volumes administered to this treatment group.  Urine pH 
ranges were similar for all groups.  Results of clinical pathology testing by treatment group 
are listed in Table 2.3. 
No differences were observed in gross or microscopic exams of any tissues between the 
control and treated animals.  Significant differences in thymus:body weight ratios were found 
between control and 3X goats but not with 1X or 5X goats.  The 3X treatment group had a 
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higher mean thymic weight (94.4g) than all other groups (67.9-82.8g) which was not 
attributable to tulathromycin treatment. 
Discussion 
 Washburn et al. (2007) demonstrated the safety of tulathromycin in adult goats at a 
single dose of 25 mg/kg (10 times the recommended dose for cattle and swine).  Moderate, 
self-limiting post-injection pain and mild swelling at the injection sites were the only adverse 
effects identified in treated animals.  The present study expanded the safety evaluation of this 
drug by 1) treating juvenile goats that would be expected to demonstrate detrimental effects 
related to tulathromycin if any were induced; 2) evaluating additional clinical pathology 
parameters and tissues; 3) using proposed label, 3X, and 5X doses to determine if any dose-
related toxicity could be appreciated; and 4) repeating each treatment weekly for three weeks 
to assess any harmful outcomes from extended drug administration.   No physical, clinical 
pathologic, or tissue differences associated with tulathromycin were detected between the 
control and treated animals.  
 The National Agricultural Statistics Service reported the U.S. meat goat inventory as 
of July 1, 2009 at 3.16 million head on 123,000 operations.
1
   The lack of approved 
antimicrobials presents a risk to this species and may contribute to unsafe off-label drug use.  
Although minimum inhibitory concentration (MIC) breakpoints have not been defined for 
bacterial species from caprines, MIC studies on cattle respiratory pathogens indicate that 
tulathromycin could be a valuable antimicrobial against goat pathogens (Evans, 2005; 
Nowakowski et al., 2004).  The current study demonstrates the safety of tulathromycin 
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administration in this species, and further investigations into pharmacokinetics and efficacy 
are warranted.   
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Table 2.1.  Parameters evaluated for differences and results between control goats and goats 
given 1X, 3X, and 5X of the label dose of tulathromycin weekly for three weeks.  
 
Physical Parameter Method of Evaluation Significance  
Body Temperature Repeated Measures Analysis NSD
a
 
Body Weight Qualitative Analysis NSD 
Respiratory Rate Qualitative Analysis  NSD 
Pulse Rate Qualitative Analysis NSD 
Daily Milk Consumption Qualitative Analysis NSD 
Hematology Parameters      
Red Blood Cells Repeated Measures Analysis NSD 
Hemoglobin Repeated Measures Analysis NSD  
Hematocrit Repeated Measures Analysis NSD 
Mean Corpuscular Volume Repeated Measures Analysis NSD 
Mean Corpuscular Hemoglobin Qualitative Analysis NSD  
MCHC Repeated Measures Analysis NSD  
Platelets Repeated Measures Analysis NSD  
White Blood Cells Repeated Measures Analysis NSD  
Total Neutrophils Repeated Measures Analysis NSD  
Total Lymphocytes Repeated Measures Analysis NSD 
Coagulation Parameters 
Prothrombin Time (PT) Pair-wise comparisons NSD 
Activated Partial Thromboplastin Pair-wise comparisons NSD  
 Time (APTT) 
Chemistry Parameters    
Alanine Transaminase (ALT) Qualitative Analysis NSD 
Sodium Repeated Measures Analysis NSD 
Potassium Repeated Measures Analysis NSD 
Chloride Repeated Measures Analysis NSD 
Calcium Qualitative Analysis NSD 
Phosphorus Qualitative Analysis NSD  
Blood Urea Nitrogen (BUN) Repeated Measures Analysis NSD 
Creatinine Repeated Measures Analysis NSD 
Glucose Repeated Measures Analysis NSD 
Total Protein Repeated Measures Analysis NSD 
Albumin Repeated Measures Analysis NSD 
 
a
NSD= No significant difference between control and any treatment groups 
b
Significant difference between control and 1X, none between control and 3X or control and 5X 
c
Significant difference between control and 3X, none between control and 1X or control and 5X 
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Table 2.1 (continued)  
 
Chemistry parameters Method of Evaluation Significance 
Globulin Repeated Measures Analysis NSD 
Albumin/Globulin ratio Repeated Measures Analysis NSD 
Aspartate Transaminase (AST) Repeated Measures Analysis NSD 
Creatine Kinase Pair-wise comparisons NSD 
Alkaline Phosphatase Pair-wise comparisons Significant difference
b
 
Gamma-glutamyl transferase (GGT) Repeated Measures Analysis NSD 
Total Bilirubin Repeated Measures Analysis NSD  
Cholesterol Repeated Measures Analysis NSD 
Triglycerides Repeated Measures Analysis NSD  
Sorbitol Dehydrogenase (SDH) Repeated Measures Analysis NSD 
Urinalysis 
Urine SG Repeated Measures Analysis NSD 
Urine Ph Repeated Measures Analysis NSD 
Fecal Parasite Burden 
Fecal exam Qualitative Analysis NSD 
Organ Weight Parameter 
Adrenal Continuous variable analysis NSD 
Brain Continuous variable analysis NSD 
Heart Continuous variable analysis NSD 
Kidney Continuous variable analysis NSD 
Liver Continuous variable analysis NSD 
Spleen Continuous variable analysis NSD 
Thymus Qualitative Analysis NSD 
Thyroid Continuous variable analysis NSD 
Organ:Body Weight Parameter  
Adrenal Gland:BW Continuous variable analysis NSD 
Brain:BW Continuous variable analysis NSD 
Heart:BW Continuous variable analysis NSD 
Kidney:BW Continuous variable analysis NSD 
Liver:BW Continuous variable analysis NSD 
Spleen:BW Continuous variable analysis NSD 
Thymus:BW Pair-wise comparisons Significant difference
c
                
Thyroid:BW Continuous variable analysis NSD 
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Table 2.2  Gross and histopathologic tissues analyzed and results for analysis for differences 
between control and tulathromycin treatment groups. 
 
Tissue Parameters Gross exam  Histopathological exam 
Abomasum ND
a 
  ND 
Adrenals ND   ND 
Aorta (abdominal) ND   ND 
Brain    
   Cerebrum ND   ND 
   Thalamus ND   ND 
   Cerebellum ND   ND 
   Medulla oblongata ND   ND 
Cecum ND   ND 
Colon ND   ND 
Duodenum ND   ND 
Epididymis (if present) ND   ND 
Esophagus ND   ND 
Eyes (with optic nerve) ND   ND 
Gallbladder ND   ND 
Heart 
   right atria ND   ND 
   right ventricle  ND   ND 
   left atria ND   ND 
   left ventricle  ND   ND 
Ileum ND   ND 
Injection site   
   first site  NSD
b
  NSD 
   other sites ND   ND  
Jejunum ND   ND 
Kidneys ND   ND 
Liver  
   medial lobe ND   ND 
   left lobe ND   ND 
Lung  
   peripheral tissue NSD  NSD 
   large bronchus NSD  NSD 
Lymph nodes  
   mandibular ND   ND 
   mediastinal ND   ND 
   mesenteric ND   ND 
 
a
ND=No abnormalities seen in control nor any treatment groups; no differences between groups 
b
NSD= No significant difference between control and any treatment groups using Fisher’s Exact 
Test 
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Table 2.2 (continued) 
 
Tissue Parameters Gross Exam  Histopathologic Exam   
Mammary gland (if present) ND   ND 
Muscle (semimembranosus) ND   ND 
Omasum ND   ND 
Pancreas ND   ND 
Peripheral nerves (sciatic) ND   ND 
Pituitary ND   ND 
Prostate (if present) ND   ND 
Rectum ND   ND 
Reticulum ND   ND 
Rumen ND   ND 
Salivary gland (mandibular) ND   ND 
Spinal cord  
   cervical ND   ND 
   thoracic  ND   ND 
   lumbar  ND   ND 
Spleen ND   ND 
Testes (if present) ND   ND 
Ovaries (if present) ND   ND 
Thymus ND   ND 
Thyroid gland/parathyroid  ND   ND  
Urethra NSD  NSD 
Urinary bladder ND   ND 
Uterus (if present) ND   ND 
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Table 2.3.  Results of clinical pathology examinations by treatment group in juvenile goats 
treated with saline or the label dose, three times the label dose, or five times the label dose of 
tulathromycin once weekly for three weeks. 
 Control Group 1X Group 3X Group 5X Group 
Parameter Mean     Range    Mean Range Mean Range Mean  Range  
RBC (x106/ml) 14.8 9.2-19.4 13.4 9.1-18.8 13.0 9.3-18.4     15.9 9.7-20.2 
HGB (gm/dl)   8.9 7.7-10.1   8.8  7.4-10.5   9.2 7.7-11.3   9.1 8.0-12.2 
Hct (%) 29.1 24.2-34.3 29.9 25.5-33.5 31.8 25.5-38.3 29.8 26.4-42.7 
MCV (fl) 20.5 14.3-36.3 23.5 15.1-35.6 25.6 18.2-39.1 19.2 14.2-38.4 
MCH (pg)   5.8 4.1-10.5   6.8 4.8-10.1   7.3 5.6-10.6   5.8 4.6-10.6 
MCHC (gm/dl) 30.5 27.5-32.5 29.5 26.7-31.7 29.1 27.4-32.0 30.5 27.5-32.8 
Platelets (x106/ml) 1.2 6.3-1.2 1.1 6.9-20.0 1.1 4.8-18.2 1.1 7.6-17.7 
WBC (x103/ml) 13.2 8.2-20.3 10.8 7.8-18.0 12.6 7.8-16.7 11.6 8.2-16.5 
-Neutros (x103/ml)   7.2 2.5-13.6   5.4 2.3-10.8   5.6 2.8-7.6 4.3 3.0-11.2 
-% Neutros (%) 53.1 26.2-68.0 43.8 25.6-71.2 45.1 17.8-58.5 47.6 23.8-66.1 
-Lymphos (x103/ml)    5.4 1.8-11.0   6.1 2.2-7.1   6.4 2.4-11.9 7.0 3.8-9.2 
-% Lymphos (%) 42.8 17.5-63.4 46.3 25.0-71.1 50.1 30.8-58.4 50.9 32.1-73.0 
PT (sec) 14.1 11.9-18.8 13.6 11.5-19.5* 12.2 11.1-13.9* 12.8 11.1-16.8* 
APTT (sec) 40.6 26.1-52.8 32.8 29.0-39.2* 30.6 22.7-36.5* 31.8 24.2-48.8* 
ALT (IU/L)   8.7 4.0-13.0   8.9 5.0-12.0   8.3 4.0-12.0   9.6 5.0-14.0 
Sodium (mEq/L) 145.6 143-147 146.4 144-148  146.3 144-149  145.8 144-148 
Potassium (mEq/L)   5.5 4.8-6.2   5.4 4.3-6.4   5.5 4.8-6.1   5.4 5.0-6.1 
Chloride (mEq/L) 109.0 106-112 108.5 106-114  109.7 105-117  108.1 105-111 
Calcium (mg/dl) 10.0 8.8-10.9 10.4 10.0-11.0* 10.7 9.9-11.4* 10.3 9.8-11.0* 
Phosphorus (mg/dl) 10.2 8.8-12.2 10.3 7.3-11.8 10.3 8.2-`12.4 10.5 8.7-12.4 
BUN (mg/dl) 10.3 7.2-12.8 10.1 6.8-19.4   9.3 7.8-12.0   9.3 5.8-18.8 
Creatinine (mg/dl)   0.4 0.3-0.7 0.4 0.3-0.5   0.5 0.3-0.6   0.4 0.3-0.5 
Glucose (mg/dl) 77.8 13-104 97.4 63-131 87.9 42-111 89.5 62-109 
Total Protein (gm/dl)   5.4 4.7-6.9 5.1 4.4-5.8   5.2 4.7-6.5   5.1 4.8-6.4 
Alb (gm/dl)   2.7 2.2-3.2 2.7 2.2-2.9   2.8 2.2-3.1   2.7 2.4-3.2 
Glob (gm/dl)    2.7 2.0-4.4 2.5 2.1-2.9   2.4 1.9-4.3   2.4 1.8-3.8 
 
 RBC (Red Blood Cell count), HGB (Hemoglobin), Hct (Hematocrit), MCV (Mean Corpuscular 
Volume),MCH (Mean Corpuscular Hemoglobin),MCHC (Mean Corpuscular Hemoglobin 
Concentration), Platelet number, WBC (White Blood Cell count), Neutros (total number and percent 
neutrophils), Lymphos (total number and percent lymphocytes, PT (Prothrombin Time), APTT 
(Activated Partial Thromboplastin Time), ALT (Alanine Transaminase), AST (Aspartate 
Transaminase), Sodium, Potassium, Chloride, Calcium, Phosphorus, BUN (Blood Urea Nitrogen), 
Creatinine, Glucose, Total Protein, Alb (Albumin), Glob (Globulin), Alb/Glob (Albumin/Globulin 
ratio), CK (Creatine Kinase), Alk Phos (Alkaline Phosphatase), GGT (Gamma-glutamyl transferase), 
Total Bili (Total Bilirubin),  Cholesterol, Triglycerides, SDH (Sorbitol Dehydrogenase), urine SG 
(specific gravity), urine pH, and fecal floatation for parasites.  * indicates significant difference at P 
< 0.10 between saline control and tulathromycin treated animals.  
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Table 2.3 (continued) 
 
Alb/Glob ratio   1.1 0.6-1.5 1.1 0.8-1.4 1.2 0.5-1.6   1.2 0.7-1.8 
AST (IU/L) 65.3 42-82 63.6 48-79 62.1 (41-78) 67.3 (48-84) 
CK (IU/L) 229.5 157-391 213.6 103-481 180.9 93-277 266.8 106-543* 
Alk Phos (IU/L) 419.4 231-655 658.8 296-1140* 642.2 299-1060 456.7 234-690 
GGT (IU/L) 61.1 39-127 48.9 36-67 53.1 31-76 51.4 35-71) 
Total Bili (mg/dl) 0.20 0.03-0.31  0.20 0.05-0.39 0.2 0.11-0.24 0.2 0.08-0.88 
Cholesterol (mg/dl) 124.4 59-197 116.4 57-193 101.2 44-150 106.6 46-158 
Triglycerides (mg/dl) 32.4 15-55 34.2 11-79 33.4 (9-72) 36.1 (12-112) 
SDH (IU/L) 48.2 18.5-98.8 50.9 23.7-111 46.7 16.7-89.5 37.9 12.1-64.3 
Urine SG 1.018 1.080-1.022 1.018 1.009-1.037 1.025 1.009-1.034 1.013 1.006-1.032 
Urine pH   6.8 5.0-8.5   7.0 5.5-8.5*   5.8 5.5-7.5*   6.2 5.0-8.5* 
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Abstract 
Tulathromycin is a macrolide antimicrobial labelled for the treatment of bacterial 
pneumonia in cattle and swine.  A tulathromycin tissue analysis method utilizing tandem 
mass spectrometry that detects the common fragment of tulathromycin in these species was 
validated using goat tissues and evaluated by specificity, linearity, recovery, accuracy, 
precision, Limit of Detection (LOD), Limit of Quantification (LOQ), and stability over time.  
The assay was then used to study tissue depletion of tulathromycin in goats.  In two different 
studies, six juvenile and ten market-age goats received a single injection of 2.5 mg/kg of 
tulathromycin subcutaneously; in a third study, 18 juvenile goats were treated with 2.5 
mg/kg, 7.5 mg/kg, or 12.5 mg/kg tulathromycin weekly with 3 subcutaneous injections.  
Mean tulathromycin tissue concentrations were highest at injection site samples in all studies 
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and all doses evaluated.  Lung tissue concentrations were greatest at day 5 (1.67 μg/g) and 
demonstrated dose-dependent increases over the doses studied.  Concentrations were below 
the level of quantification (LOQ) in injection site and lung by day 18 and in liver, kidney, 
muscle, and fat at all time points.  This study demonstrated that tissue levels in goats are very 
similar to those seen in swine and cattle. 
Introduction 
The Animal Medicinal Drug Use Clarification Act (AMDUCA) of 1994 (Food and Drug 
Administration, 1994) permits the use of certain approved animal and human drugs in an 
extralabel manner under a valid veterinary-client-patient relationship (Berge et al., 2006).  
Determination of appropriate withdrawal periods for this use is the responsibility of the 
prescribing veterinarian (Berge et al., 2006; Fajt, 2001; Fajt, 2003).  Extrapolation of data 
from other species to estimate drug behavior may increase the likelihood of violative drug 
residues in products for human consumption.   
Bacterial pneumonia is a frequent health problem in caprines, with Mannheimia 
haemolytica, Bibersteinia trehalosi, Pasteurella multocida, and Mycoplasma spp. implicated 
as the most common bacterial causes (Ackermann & Brogden, 2000; Berge et al., 2006; 
Brogden et al., 1998; Washburn et al., 2007; Yener et al., 2009; Zamri-Saad & Mera, 2001).  
Ceftiofur is the only antimicrobial presently labeled in this species (Fajt, 2001; Fajt, 2003; 
Washburn et al., 2007; Webb et al., 2004); however, cephalosporins have some limitations. 
Successful treatment requires daily administration, which may be difficult to accomplish 
under field conditions.  Concerns over cephalosporin resistance in human bacterial strains 
may lead to potential restrictions on their use in food animals (Nolen, 2009).  Additionally, 
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cephalosporins are not active against Mycoplasma species which are important pathogens of 
goats (Rosenbusch et al., 2005b).   
Macrolide antibiotics rapidly dissemination from plasma to lung tissues making them 
useful therapeutics against bacterial pneumonia (Williams & Sefton, 1993).  Newer 
macrolides display enhanced lung penetration and extended tissue half lives (Benchaoui et 
al., 2004).  Tulathromycin, a macrolide labeled to treat bacterial respiratory disease in cattle 
and swine, provides a seven day treatment with a single injection, indicating that it could be a 
useful therapeutic agent in caprines (Benchaoui et al., 2004; Evans, 2005; Nowakowski et 
al., 2004).   
Tulathromycin is manufactured as a single isomer or parent compound, designated CP-
472,295(e).  This molecule equilibrates in solution into in 9:1 mixture of two tulathromycin 
isoforms, designated CP-472,295 and 547,272, respectively (Gáler et al., 2004).  The 
common fragment or marker residue for these two different isoforms is CP-60,300, and the 
FDA-approved regulatory methodology detects this common fragment.  An alternative 
method of tulathromycin evaluation published by Gáler et al (2004) involves establishing the 
levels of the parent compound 472,295(e) and is primarily used to measure overall 
tulathromycin concentrations in plasma or lung tissue samples.   
The present study was conducted to 1) validate these methods of tulathromycin detection 
in caprine tissues and 2) to determine tissue depletion of tulathromycin over time in goats to 
provide data useful in avoiding drug residues in the human food supply.  
Materials and methods 
Analytical method for quantifying levels of CP-60,300 in tissues 
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The method used was developed by Pfizer Animal Health Group and is described in the 
Pfizer Methods 1535N-60-99-294 and 1525N-60-99-175 (NADA, 141-244, 2005).  Analysis 
for the common fragment CP-60,300 was conducted in liver, kidney, muscle, fat, and 
injection site samples using a method provided by Pfizer, Inc.  Briefly, tulathromycin 
residues were converted to the marker residue by acid-catalyzed hydrolysis with 2 N 
hydrochloric acid at 60° C.  The supernatant was passed through an OASIS® MCX (Waters, 
Milford, MA) cation exchange column and eluted with acetonitrile:ammonium hydroxide 
(95:5).  The eluate was evaporated to dryness at 50° C under a gentle stream of nitrogen (N-
Evap, Organomation Associates, Inc, Berlin, MA) and reconstituted with the aqueous mobile 
phase.  Quantification was by liquid chromatography/mass spectrometry/mass spectrometry 
(LC/MS/MS). 
Samples were injected on an Acquity® UPLC (Waters, Milford, MA); injection volume 
was 5 µL.  The mobile phase was 0.02 M ammonium acetate, pH 4.0 with formic acid-
acetonitrile (77:23) at a flow rate of 0.3 mL/min.  An Ace C8, 2.1 X 50 mm, 3 µm (MacMod, 
Chadds Ford, PA) column was maintained at 35° C.  The mass spectrometer was a Thermo 
TSQ Quantum Discovery Max (Thermo Fisher Scientific, Waltham, MA) with a heated 
electrospray ionization source operated in the positive ion mode.  Ions were monitored in the 
selective reaction monitoring mode for the common fragment and an internal standard 
(structurally similar compound provided by Pfizer) with transitions from 577.2 to 420.2 and 
591.3 to 434.2 respectively.  
Validation of the analytical method for quantifying CP60,300 in caprine tissues 
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Method proficiency in bovine tissues, specificity, linearity, recovery, accuracy, precision, 
Limit of Detection (LOD), Limit of Quantification (LOQ), stability in the final extracts, and 
stability of tulathromycin after 3 freeze / thaw cycles. The complete analytical procedure was 
applied to blank sample specimens for each tissue (liver, muscle, kidney, fat, and injection 
site).  Method proficiency was evaluated by assaying identical sets of spiked bovine and 
caprine tissues as well as incurred bovine tissue samples.  Specificity of the assay was 
considered correct if no other peak was detected at the same retention time as the marker 
residue (CP-60,300) on blank sample chromatograms.  The linearity of the method, the 
response ratio (CP-60,300 peak area / internal standard peak area) vs. concentration, was 
evaluated after analysis of the five calibration lines generated during the variation trial.  The 
calibration ranges were 25 to 250 ng.mL
-1
 and 75 to 750 ng.mL
-1
.  Linearity was calculated 
by the method of least squares linear regression of the response ratio vs. the theoretical 
concentrations, and had a tissue equivalent linearity of 0.6 to 36.0 µg/g.   In goat tissue, the 
average extraction recovery was established for concentrations of 2.75, 5.5 and 11.0 g.g
-1
 of 
liver, 1.125, 2.5 and 4.5 g.g
-1
 of muscle and fat, and 7.5, 15 and 30.0 g.g
-1
 of kidney.  Each 
spike level was analyzed in triplicate five times for an n=15.  Intraday and interday precision 
and accuracy of the analytical procedure were evaluated after replicate analyses (n = 3) of 
control goat liver, kidney, muscle and fat spiked at three concentration levels (1/2-, 1- and 2-
times the safe concentration for liver, kidney and muscle and low, medium and high 
concentrations for fat).  Using the blank samples (n = 15) from each tissue, the LOD was 
defined at the mean of the noise + 3 times the standard deviation of the mean; the LOQ  was 
defined as the mean of the noise + 10 times the standard deviation of the mean.  The noise is 
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determined at the retention time of the CP-60,300 peak.  Short-term stability was evaluated in 
the acid extract and final extract after analysis of control goat liver spiked with tulathromycin 
and stored at room temperature or refrigerated.  All samples were analyzed at 0, 1, 2, 3, 4, 7, 
10 and 14 days, and stability was assessed as the coefficient of variation between the 
standard deviation and the observed concentrations of CP-60,300.  The stability of 
tulathromycin in goat liver was evaluated after three freeze / thaw cycles (frozen for at least 
18 hours at -80˚C, thawed to room temperature).   
Lung samples were assayed for the parent compound of tulathromycin designated CP-
472,295(e) according to the protocol of Gáler et al. (2004) using ultra-high pressure liquid 
chromatography tandem mass spectrometry (UPLC-MS/MS).  Briefly, after aqueous dilution 
with internal standard, the samples were extracted by solid phase extraction (Bond-Elut 200 
mg CBA, Varian, Lake Forest, CA).  The analyte was eluted with 5:95 ammonium 
hydroxide-acetonitrile and evaporated to dryness (N-Evap, Organomation Associates, Inc, 
Berlin, MA).  Samples were reconstituted with mobile phase (82:18 0.02 M ammonium 
acetate pH 4.0 with formic acid-acetonitrile) and injected (5 µL) on the UPLC (Waters, 
Milford, MA).  The flow rate was 0.25 mL/min.  The column was an Ace C8, 2.1 X 50 mm, 
3 µm (MacMod, Chadds Ford, PA) maintained at 35° C.  The mass spectrometer was a 
Thermo TSQ Quantum Discovery Max (Thermo Fisher Scientific, Waltham, MA) with a 
heated electrospray ionization source.  Positive ions were monitored in the selected reaction 
monitoring mode with the doubly charged precursor → product ion pair of 404.1 → 578.0.  
The assay was linear from 2 to 500 ng/mL (r
2
 = 0.9883) and had a limit of detection of 0.7 
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ng/mL and a limit of quantification of 2.0 ng/mL.  Inter-assay and intra-assay variation as 
measured by %RSD were 11.1% and 11.3%, respectively.  The recovery was 99.6% ± 6.7%. 
 Animal tulathromycin studies 
Three tissue residue studies were conducted in different populations of goats.  All 
animals were acclimated prior to the study; identified by ear tags; housed individually; and 
fed ad-lib hay with goat starter ration (single-dose study) or ad-lib milk-replacer (multi-dose 
study).  Single-dose subjects were injected with tulathromycin (Draxxin®, Pfizer Animal 
Health, NY, NY) subcutaneously on the right side of the neck; goats receiving three doses 
were injected in three different subcutaneous locations.  Doses were based on body weights 
collected the day before injection.  An equal volume of sterile 0.9% sodium chloride 
(Hospira, Inc., Lake Forest, IL) was injected to control animals.   
Pre-study physical examinations were within normal limits and daily observations on 
physical attitude, appetite, and fecal consistency were recorded.  All phases of the studies 
were approved by the Institutional Animal Care and Use Committee of Iowa State University 
or the Institutional Animal Care and Use Committee of Veterinary Resources, Inc., Ames. 
IA.   
Liver, kidney, muscle, fat, lung, and injection site samples were collected, immediately 
frozen, and stored at -80
o
C until shipment for analysis.  Homogenized tissue samples from 
untreated animals were spiked with tulathromycin, frozen, and analyzed to ensure freezer 
stability of the samples throughout the storage period.  
In study 1, three male and three female, seven- to eight-week-old mixed-breed meat and 
dairy goat kids weighing 7.7-9.5 kg were randomly assigned to tissue collection time points 
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and injected with 2.5mg/kg tulathromycin subcutaneously.  Goats were humanely euthanized 
with IV xylazine to achieve general anesthesia and IV potassium chloride to induce cardiac 
arrest, and tissues were collected:  two goats at 14 days; two goats at 21 days; one goat at 28 
days; and one goat at 35 days post-injection. 
In study 2, eleven dairy-mixed breed and 19 Boer, five-to six-month-old, male (intact and 
castrated) goats weighing 13.8-27.4 kg were blocked by weight and randomly assigned to 
one of six treatment groups:  five groups injected with 2.5 mg/kg tulathromycin with various 
tissue collection time points and one saline control group.   Goats were humanely euthanized 
via a captive bolt and exsanguinated on day 5, day 12, day 18, day 27, and day 48 following 
tulathromycin injection.  One randomly selected control goat was euthanized at each time 
point.   
Study 3 was conducted to determine if multiple injections or different dosages affected 
the pharmacokinetics of tulathromycin.  Twelve male and twelve female, two- to three-week-
old, 3.4-8.3 kg,  mixed-breed meat and dairy goat kids were blocked by sex and weight and 
randomly assigned to control or one of three treatment groups receiving 2.5mg/kg, 7.5mg/kg, 
or 12.5 mg/kg tulathromycin once weekly for three consecutive weeks.  Seven days after the 
third injection, goats were humanely euthanized with IV xylazine to achieve general 
anesthesia and IV potassium chloride to induce cardiac arrest, and tissues were collected.   
Mean, standard deviation, and coefficient of variation of tulathromycin concentrations 
were calculated for each tissue type.  Differences in tissue tulathromycin between treatment 
and control market-age goats as well as overall and dose-normalized tulathromycin 
concentrations in the multi-dose treatment groups were evaluated for significance at P < 0.05 
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using a mixed model assessing least squares means differences with SAS statistical software 
(version 9.1, SAS Institute, Inc., Cari, NC).  A substitution method using ½ LOD for values 
<LOD was used for statistical comparisons.  A further assessment of this substitution method 
using the non-parametric Kruskal-Wallis test for overall tissue differences was conducted to 
evaluate for bias due to the left-censored data associated with values <LOD.  Although 
substitution methods for values <LOD are not ideal, non-parametric analysis attempts to 
minimize bias associated with unknown values below LOD. 
Results 
Method validation 
No endogenous compounds co-eluting with CP-60,300 were observed in chromatograms 
of 15 blank control goat liver and muscle samples.  The retention time of CP-60,300 was 
approximately 1.0 min.  The limit of detection for liver, muscle, kidney, fat, and injection site 
were 0.75, 0.24, 0.29 0.14, and 0.24 µg/g respectively, while the limit of quantifications were 
1.91, 0.69, 1.66, 0.61, and 0.69µg/g.  Inter- and intra- assay variation as measured by percent 
relative standard deviation (%RSD) were 4.8 and 12.7 for liver, 7.6 and 20.9 for kidney, 11.3 
and 28.6 for muscle and 4.8 and 10.7 for fat.  Recoveries were 113.6% for liver, 112.6% for 
kidney, 100.1% for muscle and 98.5% for fat.  Short-term stability percent CV ranged from 
2.5 to 11.3  and percentage of difference between the samples after 3 freeze / thaw cycles and 
prior to freezing ranged from 7.0 to 22.5in liver tissue.  The response ratio did not show a 
degradation trend over the time frames analyzed.  
Tissue sample analysis 
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Results of tissue concentrations of tulathromycin for juvenile goats given a single 
injection are listed in Table 3.1.  Tulathromycin CP-30,600 was detected only in injection 
site samples and concentrations demonstrated variability, with a 20-fold difference between 
the two goats sampled on day 14 and a 7-fold difference at day 21.  Injection site 
concentrations were below the LOD by day 35 post-injection and no CP-30,600 was detected 
in any other tissues. 
Mean tissue concentrations from the market-age goats are shown in Table 3.2.  At five 
days post-injection, only lung tissue (1.67 µg/g of CP-472,295[e]) and injection sites (7.62 
µg/g of CP-30,600) had mean tissue levels over the limit of quantification (LOQ) and had 
detectable residues in all animals tested.  Lung tissue tulathromycin concentrations also had 
the least variability in all tissues examined at all time points.  Injection site samples had the 
greatest mean values of all tissues at day 5 and day 12; values had decreased to 1.27 μg/g by 
day 18.  Mean CP-30,600 levels were below the LOQ in liver, kidney, muscle, and fat at each 
time point and in all tissues by day 18.  Control goats had no detectable tulathromycin in any 
tissues.  Tissue tulathromycin concentrations were not significantly different (P < 0.05) 
between control and treated animals in any of the examined tissues by the end of the study 
but did differ in lung tissue (CP-472,295[e]), liver (CP-30,600), fat (CP-30,600), and 
injection site (CP-30,600) over time.  No significant differences (P < 0.05) were detected 
between control and treated goats by day 18 in any of the examined tissues. 
Table 3.3 lists the tulathromycin tissue concentrations in juvenile goats given weekly 
doses for three treatments and the P values for the differences among doses.  Increasing dose 
resulted in the most dramatic tissue level increase of CP-30,600 in liver tissue; values 
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increased 385% from 2.5 mg/kg (0.7 µg/g) to 7.5 mg/kg (3.40 µg/g) and another 43% from 
7.5 mg/kg to 12.5 mg/kg (4.87 µg/g).  Tulathromycin concentration in other tissues 
demonstrated smaller increases with increasing dose, ranging from 36% of CP-30,600  in 
injection site samples in the two highest doses (7.5 mg/kg, 17.9 µg/g; 12.5 mg/kg, 24.4 µg/g) 
to 163%of CP-472,295(e) in lung samples (2.5 mg/kg, 0.72 µg/g; 7.5 mg/kg, 1.9 µg/g).   
Since liver, kidney, muscle, and fat had undetected CP-30,600 concentrations in the 2.5 
mg/kg treated animals, percent increases are difficult to determine in these tissues. 
Mean tissue concentrations normalized by dose are shown in Figure 3.1.  Dose-
normalized tissue levels of CP-30,600 were significantly different (P < 0.05) for liver 
between the 2.5 mg/kg (0.28 mg/g), and 7.5 mg/kg groups (0.45 mg/g) but not between 2.5 
mg/kg and 12.5 mg/kg (0.39 mg/g) groups.  Differences (P < 0.05) in the concentrations of 
the common fragment also existed in kidney, muscle, and fat tissue by dose between the 2.5 
mg/kg animals (<LOD) and the two higher dose groups.  No significant (P < 0.05) 
differences were found in these tissues between the two higher dose group animals, nor 
between any of the treatment groups in lung tissue or injection sites.  No tulathromycin was 
detected in any of the tissues from the saline-treated controls. 
Discussion 
The different methods for tulathromycin detection have been described for various 
matrices with different goals.  Since tissue residues detected in food animal species that have 
been treated with a specific drug are used by the FDA to establish adequate withdrawal 
periods after drug administration, detection protocols that have received regulatory approval 
must be used to evaluate these samples.  The method used to identify levels of the common 
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fragment CP- 60,300 was designed to detect concentrations of any of the tulathromycin 
isoforms; consequently, it gives the most stringent assessment of drug residues in tissues 
from treated animals.  Sample matricies for this method include those involved in drug 
absorption or elimination and/or those that may end up in the human food supply, which in 
this study include liver, kidney, fat, muscle, and injection site samples. 
Target tissue concentrations can be used in evaluating certain drugs for efficacy 
(Benchaoui et al., 2004; Gáler et al., 2004; Nowakowski et al., 2004).  This is particularly 
true for macrolide antimicrobials due to their rapid distribution out of plasma and into 
tissues.  An accurate, precise, and robust detection method is needed to characterize a drug’s 
distribution in the animal and its relationship to efficacy (Gáler et al., 2004).  Consequently, 
a detection method that focuses on the most active structure of the drug being evaluated 
provides more information on the potential therapeutic potential of the specific medication 
than overall tissue concentrations.  The method described by Gáler et al (2004) focuses on 
the evaluation of tulathromycin in lung tissues and plasma since these matricies are critical to 
determining potential drug efficacy in the tissue(s) being targeted for therapy.  This method 
identifies the parent compound of tulathromycin, CP-472,295(e), and attempts to take 
advantage of the sensitivity of tandem mass spectrometry while minimizing pre-analysis 
sample extraction and processing (Gáler et al., 2004).   
Tissue tulathromycin levels (CP-60,300 in liver, kidney, muscle, fat, and injection site; 
CP472,295[e] in lung in goats are similar to those seen in cattle and swine; results from all 
three species are shown in Figure 3.2.  Mean lung concentration in cattle at 6 days post SC 
injection was 3.01 mg/g and in swine at 7 days post intra-muscular (IM) injection was 1.44 
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mg/g (Benchaoui et al., 2004; Nowakowski et al., 2004).  Similar persistence in the lung was 
identified in goats (1.7 mg/g at 5 days) and lung was the only sample matrix that had 
significantly greater concentrations between control and treated market-age goats on day 5 
and 12, suggesting that tulathromycin is potentially a useful drug for the treatment of 
bacterial respiratory infections in this species.  Values of the common fragment at the 
injection site at days 5 and 12 were consistently higher in goats compared with cattle and 
swine, but were consistently lower by day 18 and throughout the remainder of the study.  
Values of CP-60,300 in liver, kidney, and muscle tissue at all time points were consistently 
lower in goats than in cattle and swine, and were below the LOQ at each collection date.  
Since the majority of subjects had tulathromycin concentrations below the LOQ, no true 
depletion patterns could be ascertained; however, results of this study do provide information 
on tissue disposition and removal of tulathromycin over time in goats. 
Tulathromycin has been shown to be very effective against major respiratory pathogens 
of both cattle and swine (Hart et al., 2006; Kilgore et al., 2005; Rooney et al., 2005; 
Sweeney et al., 2008).  The major benefit of macrolide antimicrobials is the persistence in 
tissues, providing sustained antibiotic levels for effective treatment.   M. Haemolytica. B. 
trehalosi, and P. multocida are frequent pathogens associated with pneumonia in goats.   
While no minimum inhibitory concentrations have been established for these bacteria in 
goats, using guidelines on breakpoints in cattle can give information on tulathromycin 
susceptibility in these agents.  A review of cases submitted to the Iowa State University 
Veterinary Diagnostic Laboratory demonstrated 95.5% (21/22) of M. haemolytica isolates, 
100% of B. trehalosi (3/3), and 100% (5/5) of P. multocida isolates were susceptible to 
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tulathromycin with mode MIC values of 8μg/ml, 4 μg/ml, and 2μg/ml, respectively.   Using 
lung tulathromycin (CP-472,295[e]) concentrations for the first 18 days, the calculated AUC 
for this period (AUClast) was 523.2 μg*hr/ml.  For modern macrolide antimicrobials, 
determination of total pathogen exposure to a given antimicrobial frequently is used to 
estimate potential efficacy of a specific drug against a specific bacterial pathogen (Evans, 
2005; McKellar et al., 2004).  AUC/MIC ratios have been used as potential indicators of 
efficacy since they incorporate both time and concentration effects to estimate this exposure 
(Evans, 2005).  In goats, the AUC/MIC ratio for the first 18 days after injection was M. 
haemolytica is 65.4, for B trehalosi is 130.8, and for P. multocida was 261.6; ratios of 25 or 
greater are indications of efficacy in this pharmacokinetic/pharmacodynamic relationship.      
 Results of the present study indicate that tissue distribution of tulathromycin is similar in 
goats to that seen in cattle and swine.  Interestingly, tissue concentrations in the juvenile 
goats were below the LOD for all tissues except injection site, while detectable levels were 
found in the older animals.  This may indicate that there is a drug tissue transport process or 
protein binding present in the market age goats that has not yet developed in very young.  
Since the majority of subjects had tulathromycin concentrations below the LOQ, no true 
depletion patterns could be ascertained; however, results of this study do provide information 
on tissue disposition and removal of tulathromycin over time in goats.  Further investigations 
into this drug in the caprine species are warranted to evaluate its usefulness in the treatment 
of bacterial respiratory disease in goats. 
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Table 3.1.  Tissue tulathromycin concentrations (µg/g) from juvenile goats receiving a single 
subcutaneous tulathromycin injection of 2.5 mg/kg by day post-injection. 
     Day 14   Day 21  Day 28  Day 35      
Tissue  # 457 # 460  # 448 # 458 # 452  # 438 LOQ  LOD  
Liver  <LOD <LOD ND <LOD  <LOD ND 1.91 0.75 
Kidney ND ND ND ND  ND ND 1.66 0.29 
Muscle  ND ND ND ND ND ND 0.69 0.24 
Fat ND ND ND ND ND ND ND 0.61 0.14  
Injection site 16.8 0.81 14.3 2.11 7.7 0.25
*
 NE NE 
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Lung  ND ND ND ND ND ND NE NE 
LOD = limit of detection; ND = none detected; * = below limit of quantification (LOQ); NE = 
not established 
 
 
 
Table 3.2.  Mean tissue tulathromycin levels (µg/g) from market-age goats receiving a single 
subcutaneous tulathromycin injection of 2.5 mg/kg by day post-injection. 
 
   Day 5 (n=5) Day 12 (n=5) Day 18 (n=5)   Day 27 (n=5) Day 48 (n=5)  
Tissue Mean SD CV% Mean SD  CV% Mean  SD CV% Mean SD CV% Mean SD  CV% 
Liver
*
 1.28
e
 0.32 24.8
a
 1.18
e
 0.42 36.0
c
 <LOD   <LOD   <LOD 
Kidney
 
<LOD    <LOD   0.51
e
 0   0
d 
0.43
e
 0.04 8.4
b
 0.31
e
 0.01 3.2
 b
 
Muscle 0.24
e
   0 0
d
 <LOD   <LOD   <LOD   <LOD 
Fat
*
 0.21
e
 0.08 35.2
b
 0.15
e
   0    0
d
 <LOD   <LOD   <LOD  
Inj. site
*
 7.62 5.65 74.2 16.5 12.2 73.9
c
 1.27 0     0
d
 NS   NS   
Lung
*
 1.67 0.24 14.4 0.64 0.13 20.2 0.23
e
  0.10 45.2 0.15
e
 0.04 27.9
a
 <LOD 
 
Inj. Site = injection site; LOD = limit of detection; NS = no sample; 
a
 one animal <LOD; 
b
 two animals 
<LOD; 
c
 three animals <LOD; 
d
 four animals <LOD; 
e
 = below limit of quantification (LOQ); * = 
significantly different concentrations over time from control animals at P < 0.05; all control goats had 
tulathromycin levels <LOD in all tissues   
 
 
Table 3.3.  Mean tulathromycin tissue levels (µg/g), SD, CV%, and P-values for differences 
between dose groups from juvenile goats receiving one injection per week of the associated dose 
for three weeks.  Tissues were collected seven days after third injection.    
           
  Dose 
    2.5 mg/kg (n=6) 7.5 mg/kg (n=6) 12.5 mg/kg (n=6)  
Tissue Mean SD CV% Mean SD  CV% Mean SD CV% P-value 
Liver 0.70
e
 0.41 57.6
 a
 3.40 0.80 23.7 4.87 0.88 18.1 < 0.0001
xyz
 
Kidney <LOD   1.65 0.64 39.2 3.28 0.40 12.1 < 0.0001
 xyz
 
Muscle 0    0.65
e
 0.34 52.4
 b
 1.33 0.68 51.3 0.0025
 yz
 
Fat 0    0.36
e
 0.23  64.5 0.65
e
 0.33 50.9 < 0.0001
 xyz
 
Injection site 8.76 7.44 85.0 17.9 8.66 48.4 24.4 8.98 37.8 0.0008
 xy
 
Lung 0.72 0.14 19.5 1.80 0.69 38.3 3.39 1.13 33.2 0.0001
 xyz 
 
LOD = limit of detection; 
a
 one animal <LOD; 
b
 two animals <LOD; 
c 
three animals <LOD;        
d
 four animals <LOD; 
e
 = below limit of quantification (LOQ); 
x
 significantly different between 
2.5 mg/kg and 7.5 mg/kg dose groups; 
y
 significantly different between 2.5 mg/kg and 12.5 
mg/kg dose groups; 
z
 significantly different between 7.5 mg/kg and 12.5 mg/kg dose groups  
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 Figure 3.1.  Dose-normalized tissue tulathromycin concentrations following administration of 
multiple subcutaneous doses of tulathromycin in goats (Capra aegagrus hircus, n=6 per group) 
at doses of 2.5, 7.5 or 12.5 mg/kg.  “X” indicates statistically significant difference from the 2.5 mg/kg 
treatment group (P < 0.05) 
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Figure 3.2.  Mean tissue tulathromycin levels (µg/g) from tissues of goats, cattle, and swine receiving 
a single subcutaneous tulathromycin injection of 2.5 mg/kg by day post-injection.  Liver, kidney, 
muscle, fat, and injection site samples were assayed for the common fragment of tulathromycin, CP-
60,300.  Lung samples were assayed for the parent compound of tulathromycin, CP-472,295 (e).  
a
 
goat lung tissues collected on day 5; 
b
 goat lung tissues collected on day 12; 
c
 goat lung 
tissues collected on day 18 
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Abstract 
Tulathromycin, a novel triamilide in the macrolide class, is labeled for treatment of 
bacterial pneumonia in cattle and swine.  The present manuscript evaluates pharmacokinetics 
of tulathromycin in goats.  In two different studies, six juvenile and ten market-age goats 
received a single injection of 2.5 mg/kg of tulathromycin subcutaneously; in a third study, 18 
juvenile goats were treated with 2.5 mg/kg, 7.5 mg/kg, or 12.5 mg/kg tulathromycin weekly 
with 3 subcutaneous injections.  Pharmacokinetic parameters estimated from the plasma 
concentrations from single injections were similar between the two groups of goats and to 
previously reported parameters in cattle and swine.  Mean terminal half lives were 59.1±7.6 
and 61.2±8.7 h and apparent volumes of distribution were 21.6±7.1 and 29.0±7.1 L/kg for 
juvenile and market age goats, respectively.  In the multi-dose study, dose-corrected AUC∞, 
apparent clearance, terminal half life, and apparent volume of distribution demonstrated 
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significantly differences at P < 0.05 among repeated injections but not among doses.  
Overall, pharmacokinetic parameters in goats are similar to those reported in cattle and 
swine, and tulathromycin may prove a useful drug for treating respiratory disease in goats. 
Introduction 
Bacterial pneumonia is a frequent cause of morbidity and mortality in the caprine species 
(Washburn et al., 2007; Yener et al., 2009).  The most common bacterial species associated 
with caprine pneumonia include Mannheimia haemolytica, Bibersteinia trehalosi, 
Pasteurella multocida, and Mycoplasma spp.(Ackermann & Brogden, 2000; Berge et al., 
2006; Brogden et al., 1998; Washburn et al., 2007; Yener et al., 2009; Zamri-Saad & Mera, 
2001).   
Drugs that are FDA-approved for use in goats are severely limited, and often must be 
administered in an extra-label manner (Berge et al., 2006).  Currently ceftiofur is the only 
labeled antimicrobial available (Fajt, 2001; Fajt, 2003; Washburn et al., 2007; Webb et al., 
2004).  Due to the concern over increased cephalosporin resistance in human bacterial strains 
and its potential association with use of this antibiotic in food animals, restrictions may be 
imposed on use of cephalosporins in food animals (Nolen, 2009).  Additionally, Mycoplasma 
species are important pathogens of goats and cephalosporins are not expected to be active 
against these bacteria (Rosenbusch et al., 2005).  The choice of a suitable antimicrobial to be 
used off label in goats must often be made based on clinical experience or on data collected 
in other species. 
Tulathromycin is a novel triamilide antimicrobial in the macrolide class shown to be safe 
and effective in cattle and swine to treat bacterial respiratory disease (Benchaoui et al., 2004; 
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Evans, 2005; Nowakowski et al., 2004).  Macrolide structure facilitates rapid distribution of 
these drugs from the blood stream into tissues (Williams & Sefton, 1993). Newer macrolides, 
such as azithromycin and tulathromycin, have increased lung tissue uptake and longer half 
lives than older macrolides such as erythromycin (Benchaoui et al., 2004).  In addition, the 
triple-ionized form of tulathromycin produces displacement of the Mg
2+
 ions present in the 
outer cell wall of gram negative bacterial pathogens, facilitating drug entry into these agents 
(Evans, 2005).  Tulathromycin demonstrated a 90% reduction in bacterial number (MIC90) 
against the following agents collected from diseased tissues in cattle:  M. haemolytica at 2 
µg/ml; P. multocida at 1 µg/ml; and M. bovis at 1µg/ml (Evans, 2005).  Since goats are 
susceptible to many of the same bacterial agents as cattle, tulathromycin could be a useful 
therapeutic agent in the caprine species.  The present study was conducted to establish 
pharmacokinetic behavior of tulathromycin in goats.  
Materials and methods 
Study Design 
Three studies were conducted in different populations of goats.  All animals were 
acclimated prior to the initiation of the study; were identified by individual ear tags; were 
housed individually; and were fed ad-lib hay with goat starter ration (single-dose study) or 
milk-replacer (multi-dose study).  Animals receiving a single dose of tulathromycin 
(Draxxin®, Pfizer Animal Health, NY, NY) were injected on the right side of the neck; goats 
receiving three doses were injected in a different location for each injection.  Doses were 
based on body weights collected the day before injection.  Single-dose studies were not 
randomized since all animals received the same dose.  Results of pre-study physical 
88 
 
 
 
examinations were within normal limits and daily observations on physical attitude, appetite, 
and fecal consistency were recorded.  All phases of the studies were approved by the 
Institutional Animal Care and Use Committee of Iowa State University and Veterinary 
Resources, Inc.  Blood samples were collected into sterile glass tubes containing lithium 
heparin as an anticoagulant; centrifuged within one hour of collection; transferred to a sterile 
cryovial; and stored at -80
o
C until shipment for analysis.  Plasma samples obtained prior to 
treatment were spiked with tulathromycin to establish freezer stability standards and 
analyzed to ensure stability of the samples throughout the storage period.  
Single-Dose study—juvenile goats 
Three male and three female, six week old mixed-breed meat and dairy goat kids with a 
mean body weight of 8.4 kg (range =7.7-9.5 kg) were injected with 2.5mg/kg tulathromycin 
subcutaneously.  Plasma samples were collected from the jugular vein prior to injection, and 
at 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, and 
360 hr following injection.   
Single-Dose study—market age goats 
Five dairy-mixed breed and five Boer, six month old, male (intact and castrated) goats 
with a mean body weight of 19.9 kg (range = 17.2-27.4 kg) received one subcutaneous 
injection of 2.5 mg/kg tulathromycin.   Blood samples were collected from the jugular vein 
prior to injection, and at 1, 2, 4, 6, 8, 10 min; and 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, 96, 120, 
144, 168, 192, 216, 240, 264, 288, 312, 336, and 360 hr following injection  
Multi-dose study—juvenile goats 
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The multi-dose study was conducted to evaluate effects of multiple injections using three 
different dosages of tulathromycin.  Nine male and nine female, one to two week old mixed-
breed meat and dairy goat kids with a mean body weight of 5.15 kg ( range = 3.4-8.3 kg) 
were blocked by sex and weight and randomly assigned to one of three treatment groups 
receiving 2.5mg/kg, 7.5mg/kg, or 12.5 mg/kg tulathromycin once a week for three weeks.  
Blood samples were collected from each animal prior to the first injection, at 4, 52, 100, and 
148 hr after each of the first two injections and 4, 52, 100, and 164 hours after the third 
injection.   
Tulathromycin Analysis 
Persons performing tulathromycin analysis were blinded to information on treatment 
group in the multi-dose study.  Samples were assayed for tulathromycin according to the 
protocol of Gáler et al. (2004) using ultra-high pressure liquid chromatography tandem mass 
spectrometry (UPLC-MS/MS).  Briefly, after aqueous dilution with internal standard, the 
samples were extracted by solid phase extraction (Bond-Elut 200 mg CBA, Varian, Lake 
Forest, CA).  The analyte was eluted with 5:95 ammonium hydroxide-acetonitrile and 
evaporated to dryness (N-Evap, Organomation Associates, Inc, Berlin, MA).  Samples were 
reconstituted with mobile phase (82:18 0.02 M ammonium acetate pH 4.0 with formic acid-
acetonitrile) and injected (5 µL) on the UPLC (Waters, Milford, MA).  The flow rate was 
0.25 mL/min.  The column was an Ace C8, 2.1 X 50 mm, 3 µm (MacMod, Chadds Ford, PA) 
maintained at 35° C.  The mass spectrometer was a Thermo TSQ Quantum Discovery Max 
(Thermo Fisher Scientific, Waltham, MA) with a heated electrospray ionization source.  
Positive ions were monitored in the selected reaction monitoring mode with the doubly 
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charged precursor → product ion pair of 404.1 → 578.0.  The assay was linear from 2 to 500 
ng/mL (r
2
 = 0.9883) and had a limit of detection of 0.7 ng/mL and a limit of quantification of 
2.0 ng/mL.  Inter-assay and intra-assay variation as measured by %RSD were 11.1% and 
11.3%, respectively.  The recovery was 99.6% ± 6.7%. 
Pharmacokinetic analysis 
Plasma tulathromycin concentrations in the juvenile and market-age goats following the 
single dose of tulathromycin were analyzed for each individual animal by compartmental and 
non-compartmental approaches (NCA) with the software WinNONLIN
®
 version 5.2.1 
(Pharsight Corporation, Mountain View, CA).     Biexponential equations for a two-
compartment open model   Cp = Ae
-αt
 +  Be
-βt
   (where A and B are y-intercept constants, α is 
the rate constant of the distribution phase, and β is the rate constant of the elimination phase) 
were used to fit the observed data.  Weighting of the data using the inverse square of the 
concentration was used to improve the line fits and residual plots.  The goodness of fit of the 
data with the model was determined by visual examination of the line fits, residual plots, and 
Akaike’s information criteria (Yamakoa et al., 1978).   Because the first sample obtained in 
the juvenile goats was the observed Cmax, only data points after the Cmax in the market age 
goats were used in the comparison.  
In addition, non-compartmental analyses (NCA) were performed on the individual goat 
plasma concentrations for both groups of goats from the single dose studies and the juvenile 
goats from the multi-dose study.  Calculated non-compartmental parameters include the area 
under the time-concentration curve (AUC) from time 0 to infinity (AUC∞); the area under the 
curve divided by the dose (AUC∞/D); the mean transit time (MTT); apparent whole body 
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clearance (CL/F); the terminal elimination phase rate constant and its half life (λz and t ½ λz); 
and the apparent volume of distribution (Vz/F).  The maximum plasma concentration (Cmax) 
and the time to maximum concentration (Tmax) were collected directly from the data. 
For the multi-dose study, WinNonLin would normally use the trough concentration, 
which would be taken immediately prior to the next consecutive dose for use in estimating 
NCA parameters.  Due to technical constraints a trough concentration was not obtained prior 
to the 2
nd
 and 3
rd
 doses in this study.  To determine if the lack of a trough concentration 
significantly affected the pharmacokinetic results, a comparison was made among the 
WinNonLin-estimated AUC∞ for each dosing interval (1
st
, 2
nd
 and 3
rd
 dose) with the initial 
plasma concentration for the 2
nd
 and 3
rd
 dose set to an upper limit of the last measured 
concentration at 24 hr prior to next dose (AUCupper) versus when the initial dose was set to 
zero (AUClower ) by default in WinNonLin.  The percentage difference in the AUC was 
calculated as  
 
The actual AUC∞ will be somewhere between the two estimates; therefore if the 
percentage differences between AUCupper and lower AUClower was small, then the lack of an 
actual trough sample was assumed to not affect the pharmacokinetic analysis significantly.  
Statistical analysis 
Mean, standard deviation (SD) and coefficient of variation  were calculated for each 
parameter in each treatment group.  Results of pharmacokinetic parameters were assessed for 
differences between study groups using the Students t-test with SAS statistical software 
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(version 9.2, SAS Institute, Inc., Cary, NC).  Parameters for each goat from the multi-dose 
groups were evaluated for significant differences (P < 0.05) from either dose level or 
injection repetition by a Two-Way ANOVA (Prism for Windows v 5, GraphPad Software, 
Inc., La Jolla, CA).  A Bonferroni post hoc test was used to determine significant differences 
among specific doses and repetitions, if the ANOVA showed statistically significant effects. 
Results  
Single dose 
Individual animal results as well as mean, standard deviation (SD), and coefficient of 
variation (C V) from compartmental and non-compartmental analysis for juvenile and market 
age goats that received a single subcutaneous tulathromycin injection are listed in Tables 4.1 
and 4.2, respectively.   The comparison of the compartmental fits of the elimination phase 
with the observed plasma concentrations for the juvenile and market age goats are shown in 
Figures 4.1A and 4.1 B, respectively.  For the majority of the juvenile goats and the market 
age goats, the WinNonLin-defined terminal phase was used for calculation of the NCA 
pharmacokinetic parameters.  However for goats 452 and 458, WinNonLin included only 3 
or 4 time points to estimate the terminal phase, and the estimated half lives were greater than 
the time period during which they were calculated.  Therefore for those 2 goats the terminal 
phase was selected for a period that maximized R
2 
and also included at least 5 data points and 
was at least 3 times greater than the estimated half life.  For the market age goats, the 
WinNonLin-selected terminal period included only 3 points for goats 28, 35, and 77.  For 
that reason the NCA pharmacokinetic parameters were estimated by a user-defined terminal 
period according to the criteria described for the juvenile goats. 
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 Mean values, SD, and P values derived from assessing the groups for differences using 
the Student t-test are listed in Table 4.3.  Significant differences (P < 0.05) were found 
between the groups for the NCA parameters mean AUC∞ (juvenile-10580 ng-h/ml; market-
age 7918 ng-h/ml) and mean CL/F (juvenile-250.3 nl-kg/hr; market-age 327.7 nl-kg/hr); and 
the compartmental parameters mean α (juvenile-0.62 hr-1; market-age 0.41 hr-1) and mean t½α 
(juvenile-1.20 hr; market-age 2.01 hr).  No other parameters were significantly different 
between the groups.  AUC∞ values from the compartmental and non-compartmental models 
were within 10% of each other for all of the juvenile goats and eight of the ten market age 
goats.  Mean β phase values from the compartmental model for the juvenile and market age 
animals (0.012 and 0.011 hr
-1, respectively) were comparable to the λz values calculated from 
the non-compartmental model (0.012 and 0.011 hr
-1
, respectively). 
Multi-dose 
The estimated terminal phase for each injection at all three dose levels from the multi-
injection study are shown in Figure 4.2., and non-compartmental pharmacokinetic parameters 
are shown in Figure 4.3.   The differences in the AUC∞ calculated with an initial plasma 
concentration of zero versus the upper limit of the concentration were all less than 1%; with 
the highest at 0.65% (data not shown).  Therefore the pharmacokinetic parameters were 
compared for estimates from the WinNonLin default concentration of zero for the initial 
plasma concentration at the time of injection for the multiple doses.   
Assessment of pharmacokinetic parameters in the multi-dose animals detected several 
unique findings.  While mean AUC∞ increased slightly greater than the increase in dose 
among the dose levels, the dose-normalized AUC∞ were not significantly different among 
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doses at P < 0.05 (Figure 4.3A).  At the highest dose of 12.5 mg/kg, the dose-normalized 
AUC∞ was significantly lower (P < 0.05) for the second and third injections compared with 
the first injection.  Terminal half life was significantly higher (P < 0.05) for all dose groups 
between the second and third injections and between the first and third injections in the 
highest dose group (Figure 4.3 B).  For all dose levels apparent clearance, CL/F, was 
significantly higher (P <0.05) from injection 3 compared with injection 1, and from injection 
2 compared to injection 1 for the two higher dose (7.5 mg/kg and 12.5 mg/kg) groups (Figure 
4.3 C).  There was a statistically significant difference at P < 0.05 in apparent volume of 
distribution, Vz/F, for injection 3 compared with injection 1 for all doses.  In addition, Vz/F 
was significantly greater between injections 2 and 3 for the lowest dose (2.5 mg/kg) group 
and between injections 1 and 2 for the highest dose (12.5 mg/kg) group (Figure 4.3 D).  The 
concentration measured at 4 hr post administration was the highest measured concentration 
following each injection for all 3 dose levels.  The dose-normalized Cmax decreased with 
repeated injections for all 3 dose levels, but the decrease was only statistically significant (P 
< 0.05) at the highest dose of 12.5 mg/kg (Figure 4.3 E).  This decrease in Cmax with repeated 
injection contributed to the injection-dependent decrease in AUC∞.  No differences in MTT 
were noted between doses or repeated injections (Figure 4.3 F). 
Discussion  
The pharmacokinetic parameters of tulathromycin following a single subcutaneous 
injection in goats in this study demonstrated similar ranges and variability to those reported 
in cattle (Gáler et al., 2004; Nowakowski et al., 2004) and swine (Benchaoui et al., 2004).  
Mean Cmax reported for animals administered 2.5 mg/kg ranged from 300 to 1300 ng/ml in 
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cattle and from 585 to 1100 ng/ml for swine; the mean Cmax in this study was 988 ng/ml for 
the juvenile goats and 1185 ng/ml for the market age goats.  One limitation to the previous 
data in cattle and swine and to the juvenile goats in this study was the absence of an 
absorption phase during the time points collected for determination of the plasma 
concentrations of tulathromycin.  This study adjusted the sampling times to collect more 
frequent samples at early time points in the market age goats, and therefore, the observed 
Tmax (mean of 13.3 min) and Cmax (1185 ng/ml) are more accurate estimates of the peak time 
and  concentration of tulathromycin.   The reported plasma AUC∞ ranged from  11,200 to 
18,700 ng/ml for cattle, and 9000 to 15,600 ng/ml for swine compared with a mean ± SD of 
10,580 ± 2743 ng/ml for the single-dose juvenile goats and 7918  ± 1594 ng/ml for market 
age goats in this study.  Terminal phase half life for a single administration of tulathromycin 
have been reported to be 87 to 110 hours for plasma samples in cattle and 39.8 to 91 hours in 
swine compared with the estimates of 59.1 hours in juvenile goats, and 61.2 hours in market 
age goats in this study.  Variability such as that seen in these studies is not unexpected and 
had been reported in pharmacokinetic research, especially with subcutaneous routes of  
administration  (Riviere, 1999). 
The terminal phase half lives measured in the market age goats in this study are shorter 
than a recent study (t ½ 117.9 ±33.9 hr), which also analyzed the pharmacokinetics of 
tulathromycin following a single dose of 2.5 mg/kg administered subcutaneously in 5-7 
month old goats (Young et al., 2010).  In that study, however, sampling was conducted for a 
longer duration (456 hours post administration) and a different analytical technique was used.  
In the present work, a shorter sampling period was used with more frequent collections 
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during the absorption phase, which influenced the calculation of the half life.  In both of 
these tulathromycin studies in goats, sampling periods contained at least 3 half lives but not a 
more ideal period of 5-7 half lives.  In addition, the percentage of the AUC∞ that was 
extrapolated was small, with a mean 3.4% and 3.0% for the adult goats from the Young et al. 
(2004) study and market age goats from this study, respectively.  
The half lives for tulathromycin from the juvenile goats in this study following a 
single dose were longer than those estimated for the multi-dose study.  The data from the 
multi-dose study was sparse due to experimental limitations and samples were collected for 
only 7 days after each injection; therefore the estimated half lives most likely do not 
represent the actual terminal phase.  The time period for the estimate was consistent among 
injections and dose levels so evaluation for effects of dose or repeat on the pharmacokinetics 
of tulathromycin in juvenile goats is valid.  Of note from the multi-dose study was the 
significant increase in the apparent clearance and volume of distribution with repeated 
injections.  This was a result of the decrease in dose-normalized AUC∞ due to lower Cmax 
values.  Since with extravascular administration, only the apparent clearance and volume of 
distribution can be calculated, the increase may reflect decreased bioavailability of the 
administered tulathromycin.  An increase in elimination could result in a lower Cmax and an 
increase in apparent clearance, however, the terminal half life was not significantly lower 
with each repeated injection.  In addition, Cmax may have been missed by four hours post-
injection.  The large value of Vz/F for all three dose levels indicated extensive peripheral 
distribution for tulathromycin in the goats.  Experimental design did not allow a trough 
sample to be collected immediately prior to the next tulathromycin injection, which would be 
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ideal.  To verify that the lack of the trough sample did not affect the statistical comparison of 
the AUC∞ and other parameters calculated with AUC∞, an upper limit of the concentration 
measured at 24 hours prior to the subsequent injection was used.  The increase in the AUC∞ 
would be less than 1 %, which is significantly less than the 33% decrease in the dose-
normalized AUC∞ with repeated injection. 
Apparent clearance was significantly lower in juvenile goats than in the market-age 
animals.  Although no information is currently available on the metabolism of tulathromycin, 
clearance of other long-acting macrolides are primarily through bile elimination with a small 
percentage excreted unchanged in the urine (Farrington, 1998; Williams & Sefton, 1993).    It 
had been shown that in both animals and humans production and activity of bile acids is 
limited early in life and improves around weaning (Kussaibati et al., 1982; Pettigrew and 
Moser, 1991; Watkins, 1985).   The juvenile goats studied here were two weeks old at study 
initiation and five weeks old at study termination, and diminished bile acid metabolism may 
have influenced drug clearance in these animals, which would also account for the greater 
mean value for AUC∞ in juvenile goats over market age subjects.   
There currently are limited antimicrobials available for treatment of bacterial 
infections in goats, which are increasingly being used in food-production.  Pharmacokinetic 
data on potential drugs is critical to ensure effective treatment and safe food for human 
consumption.   Tulathromycin has been shown to be very effective against major respiratory 
pathogens of both cattle and swine (Godinho et al., 2005; Hart et al., 2006; Kilgore et al., 
2005; Schunicht et al., 2007).  Pharmacokinetic data on potential drugs is critical to ensure 
effective treatment and safe food for human consumption.   Results of this study indicate that 
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tulathromycin behaves similarly in goats to cattle and swine and may represent a useful 
therapeutic in the caprine species.  
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Table 4.1.  Compartmental and non-compartmental pharmacokinetic parameters for juvenile 
goats (Capra aegagrus hircus ; 8 weeks of age) given a single 2.5 mg/kg subcutaneous 
injection of tulathromycin.  CL/F and V/F were compared as estimates of clearance and 
volume of distribution, respectively, since no IV administration was performed. 
               
     Compartmental parameters 
 A  B  α  β   AUC∞  t ½ α  t ½ β  
Animal (ng/ml)  (ng/ml)  hr-1   hr-1  (ng-hr/ml)  (hr) (hr)  
438   671.9  162.1  0.63 0.012 14166 1.11 56.0   
448  1254.1  117.1  0.90 0.012 11403 0.77  59.3  
452   709.9   95.1  0.72 0.012   9199 0.97 59.8  
457    905.9    87.1  0.55 0.011   9270 1.25  60.7  
458   594.2   59.7  0.48 0.010   6986 1.45 66.7  
460   464.4  120.8  0.42 0.013 10575 1.64 54.4  
Mean   766.7    107.0   0.62 0.012 10266 1.20 59.5  
SD   279.4   34.9  0.17  0.001 2428 0.32 4.3  
CV%   36.4   32.7  28.4 7.0 23.7 26.6  7.2  
   Non-compartmental parameters 
 AUC∞ AUC∞/D MTT CL/F λz  t ½ λz Vz/F  Cmax Tmax  
Animal (ng·hr/ml)  (ng-h-kg/ml/mg)   (hr) (ml/hr/kg) (hr-1) (hr)  (L/kg)  (ng/ml)   (hr)   
438 15004 6002 70.5 166.6 0.013 54.2 13.0     880.7 0.25 
448 11601 4640 72.3 215.4 0.013 55.3 17.2 1322.0 0.25 
452  9391 3756 73.5 266.2 0.009 73.8 28.4 1007.0 0.25 
457  9597 3839  70.1 260.4 0.012 59.4 22.3 1179.0 0.25 
458  6792 2717 71.9 368.1 0.012 58.9 31.3   793.1 0.25 
460 11095 4438 65.0 225.3 0.013 52.7 17.1   744.3 0.25 
Mean 10580 4232 70.6 250.3 0.012 59.1 21.6   987.7  0.25 
SD 2743 1097  3.0 67.9  0.001   7.6  7.1     226.8 0.25  
CV%  25.9  25.9    4.2 27.1  11.2 13.0 33.0    23.0  0.25 
 
A, distribution intercept; B, elimination intercept; α, distribution constant; β, elimination 
constant; AUC∞, area under the plasma concentration vs. time curve extrapolated to infinity; t 
½ α, distribution half-life; t ½ β, elimination half-life; AUC∞/D, area under the plasma 
concentration vs. time curve extrapolated to infinity/Dose; MTT, mean transfer time; CL/F, 
apparent clearance; λz, elimination rate constant; t ½ λz, elimination half-life; Vz/F, apparent 
volume of distribution; Cmax, observed maximum plasma concentration; Tmax, time to 
observed maximum plasma concentration 
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Table 4.2.  Compartmental and non-compartmental pharmacokinetic parameters in market 
aged goats (Capra aegagrus hircus ; 20 weeks of age) given a single 2.5 mg/kg subcutaneous 
injection of tulathromycin.  CL/F and V/F were compared as estimates of clearance and 
volume of distribution, respectively, since no IV administration was performed.             
  
  Compartmental parameters 
  A  B α β AUC∞ t ½ α  t ½ β    
Animal    (ng/ml)  (ng/ml)  hr-1  hr-1   (ng*hr/ml) (hr)  (hr)   
 10   414.4   100 0.32 0.011 10024 2.16 60.3  
 13   906.1  59.3  0.27  0.012 8355 2.57 58.4  
 28   195.1  40.8  0.16  0.009 5646 4.38 75.0  
 30   766.9  43.1 0.43 0.009 6654 1.62 78.2  
 35   644.1  129 0.47   0.012 12168 1.47 58.1  
 36   867.3  96.1  0.53  0.012 9634 1.30 57.7  
 39   926.3  53.5  0.62  0.009 7413 1.12 76.6  
 67   686.0  82.5  0.50  0.014 7376 1.40 50.4  
 77   352.4  86.6  0.24  0.012 8510 2.90 56.3  
 78    1063.0 98.2  0.57  0.013 9507 1.22 53.9  
Mean   682.2  78.9  0.41  0.011 8528 2.01 62.5  
SD    282.0  28.8 0.15  0.002 1888 1.03 10.1  
CV%   41.3   36.4  37.7 15.0  22.1  51.0 16.2  
     Non-compartmental parameters 
 AUC∞ AUC∞/D MTT CL/F λz t ½ λz Vz/F Cmax Tmax  
Animal (ng·hr/ml) (ng*h*kg/mL/mg)   (hr)  (ml/hr/kg) hr-1 (hr)  (L/kg)  (ng/ml)  (hr)   
10 10731 4292 74.8 233.0 0.012 56.5 19.0 924.5 0.25 
13  7301 2921  55.6  342.4 0.010 72.0 35.5 1265.0 0.17 
28  5342 2137 67.9 468.0 0.012 56.6 38.2 325.0 0.25 
30  6769 2708 77.7 369.3 0.010 70.3 37.5 1304.0 0.17 
35  8984 3594 74.4 278.3 0.009 76.2 30.6 1529.0 0.25 
36  8901 3560 66.2 280.8 0.012 56.6 22.9 1123.0 0.17 
39  7308 2923  75.7 342.1 0.011 61.3 30.3 1520.0 0.25 
67  6750 2700 61.7 370.4 0.013 54.7 29.2 1296.0 0.25 
77  7471 2988 65.7  334.6 0.012 56.0 27.0  576.3 0.17 
78  9578 3831 62.0 261.0 0.014 48.7 18.3 1988.0 0.25 
Mean  7914 3165  68.2 328.0 0.011 60.9 28.8 1185.0 0.22 
SD  1600   640   7.3   68.1 0.001  8.9   7.1 481.8 0.04 
CV%   20.2  20.2 10.7  20.8  13.8 14.6 24.7  40.7 19.8 
 
A, distribution intercept; B, elimination intercept; α, distribution constant; β, elimination 
constant; AUC∞, area under the plasma concentration vs. time curve extrapolated to infinity; t 
½ α, distribution half-life; t ½ β, elimination half-life; AUC∞/D, area under the plasma 
concentration vs. time curve extrapolated to infinity/Dose; MTT, mean transfer time; CL/F, 
apparent clearance; λz, elimination rate constant; t ½ λz, elimination half-life; Vz/F, apparent 
volume of distribution; Cmax, observed maximum plasma concentration; Tmax, time to 
observed maximum plasma concentration 
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Table 3. Mean, SD and T-test P-values for non-compartmental and compartmental 
pharmacokinetic parameters calculated from plasma tulathromycin concentrations following 
administration of a single 2.5 mg/kg subcutaneous injection of tulathromycin in juvenile 
(n=6) and market age (n=10) goats (Capra aegagrus hircus).  CL/F and V/F were compared 
as estimates of clearance and volume of distribution, respectively, since no IV administration 
was performed.               
 
Pharmacokinetic   Juvenile goats        Market Age goats   t-test  
Parameter    Mean    SD  Mean  SD   P- value  
AUC∞ (ng*h/mL)  10580 2743   7918   1594  0.030 
AUC∞/D (ng*h*kg/mL/mg)      4232 1097    3167   638  0.030 
MTT (hr)        70.6     3.0  68.3     7.1  0.985 
CL/F (nl/hr/kg)      250.3   67.9   327.7    67.9  0.053  
λz (hr
-1
)    0.012   0.002   0.011  0.001  0.995 
t ½ λz (hr)        59.1    7.6  61.8       8.7 0.529 
V/F (L/kg)       26.4   16.4  31.4     14.5 0.146 
Cmax (ng/ml)    987.8   226.9    1185  481.8 0.367 
A (ng/ml)      766.7   279.4   682.2   282.0 0.570 
B (ng/ml)      107.0    34.9  78.9   28.8 0.102 
α (hr-1)      0.62    0.17  0.41  0.15 0.027 
β (hr-1)     0.012 0.001   0.011   0.002 0.633 
AUC∞   (ng*h/mL)  10266  2428 8529   1888 0.131  
t ½ α (hr)      1.20   0.32 2.01   1.03 0.082 
t ½ β (hr)     59.5   4.27 62.5    10.1 0.504 
 
 
AUC∞, area under the plasma concentration vs. time curve extrapolated to infinity; 
AUC∞/D, area under the plasma concentration vs. time curve extrapolated to infinity/Dose; 
MTT, mean transfer time; CL/F, apparent clearance; λz, elimination rate constant; t ½ λz, 
elimination half-life; Vz/F, apparent volume of distribution; Cmax, observed maximum 
plasma concentration; Tmax, time to observed maximum plasma concentration 
A, distribution intercept; B, elimination intercept; α, distribution constant; β, elimination 
constant; AUC∞, area under the plasma concentration vs. time curve extrapolated to infinity;  
t ½ α, distribution half-life; t ½ β, elimination half-life 
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 Figure 4.1. Plasma concentrations (symbols) of tulathromycin for A) individual juvenile 
goats (Capra aegagrus hircus ; 8 weeks of age) and B) market aged goats (Capra aegagrus 
hircus ; 20 weeks of age) given a single 2.5 mg/kg subcutaneous injection of tulathromycin 
plot against the mean predicted tulathromycin (line) during the elimination phase.  The 
compartmental parameters used to generate the predicted concentration are given in Tables 1 
and 2.  Each symbol represents values from one animal. 
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Figure 4.2.  Mean ± SD of  plasma concentrations from kid goats administered 3 repeated  
injections of 2.5, 7.5 or 12.5 mg/kg tulathromycin at 7 day intervals.  The predicted plasma 
concentrations for the terminal phases estimated from a noncompartmental analysis of the 
data are plotted for each injection at each dose level.  The parameters from the NCA are 
given in Table 3. 
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Figure 4.3.  Mean ± SD of NCA parameters estimated from kid goats from multi-dose administration of 2.5, 7.5, or 12.5 mg/kg tulathromycin 
including A) Dose-normalized AUC2∞; B) terminal half life(t1/2); C) apparent clearance (CL/F);  D) apparent volume of distribution (V/F);  E) 
dose-normalized Cmax; and F) Mean Transit Time (MTT).  The parameters were analyzed by a 2 way ANOVA at P < 0.05 with a Bonferroni post 
hoc test (P < 0.05).  Bars marked with 
a
 indicate a statistically significant difference (P < 0.05) from injection 1, and 
b
 indicates a statistically 
significant difference (P < 0.05) from injection 2. 
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CHAPTER 5.  ANTIMICROBIAL SUSCEPTIBILITY PATTERNS AND 
SENSITIVITY TO TULATHROMYCIN IN GOAT RESPIRATORY 
BACTERIAL ISOLATES 
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Kristin A. Clothier, DVM; Joann M. Kinyon, MS, Ronald W. Griffith, DVM, MS PhD 
 
Abstract 
Bacterial pneumonia is a common and often life-threatening respiratory problem in both 
meat and dairy goats.  Options for approved antibiotic therapy in goats to combat these 
bacterial infections are severely limited and frequently drugs must be used in an extra-label 
manner.  Tulathromycin, a triamilide macrolide antimicrobial drug shown to be effective 
against swine and cattle respiratory bacterial agents, has been identified as a potentially 
useful drug in caprines.  The present study was conducted to determine the susceptibility of 
recognized bacterial respiratory pathogens to commonly prescribed antimicrobials, with a 
particular emphasis on the efficacy of tulathromycin against these agents.  Minimum 
inhibitory concentration (MIC) testing using microbroth dilution was performed on a 
collection of forty-five Mannheimia haemolytica, eleven Pasteurella multocida, and eleven 
Bibersteinia trehalosi isolates from the lungs of goats with clinical pneumonia.  To further 
characterize efficacy of tulathromycin against these pathogens, minimum bactericidal 
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concentration (MBC) testing and kinetic killing assays were conducted.  Most of the isolates 
were susceptible to the antimicrobials tested; however, increased resistance as demonstrated 
my higher MIC values was seen in all species to penicillin, in P. multocida to 
sulfadimethoxine, and in B. trehalosi to the tetracyclines.  All isolates were susceptible to 
tulathromycin, which demonstrated a high killing efficiency in both bactericidal assays.  
Results of this study indicate that most goat pneumonic bacterial pathogens remain 
susceptible to commonly-prescribed antibiotics, although some evidence of resistance was 
seen to certain drugs; and that tulathromycin is highly effective against goat respiratory 
pathogens which could make it a valuable medication in this species. 
Introduction 
Bacterial pneumonia is a common and often life-threatening respiratory problem in both 
meat and dairy goats (Washburn et al., 2007; Yener et al., 2009).  Pasteurella multocida, 
Mannheimia haemolytica, and Bibersteinia trehalosi (formerly M. haemolytica serotype T) 
often complicated by Mycoplasma colonization, are the most common causes of respiratory 
disease in sheep and goats  (Ackermann & Brogden, 2000; Berge et al., 2006; Brogden et al., 
1998; Washburn et al., 2007; Zamri-Saad & Mera, 2001).  Options for approved antibiotic 
therapy to combat these bacterial infections are severely limited (Berge et al., 2006).  
Currently ceftiofur is the only antibiotic labeled for use in goats; however, successful 
treatment relies on daily therapy which may be difficult to accomplish in field situations 
(Fait, 2001; Fait, 2003; Washburn et al., 2007; Webb et al., 2004).   
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The Animal Medicinal Drug Use Clarification Act (AMDUCA) of 1994 permits the use 
of certain approved animal and human drugs in an extra-label manner under a valid 
veterinary-client-patient relationship (Berge et al., 2006; Fait, 2001; Fait, 2003; Food and 
Drug Administration, 1994).  Prescribing veterinarians are responsible for choosing an 
appropriate drug, dose, and withdrawal period in the absence of  label directions for the 
species being treated (Fajt, 2001).  Minimum inhibitory concentration (MIC) data on 
antimicrobials most likely to be effective against known pathogenic respiratory isolates could 
prove useful to clinicians. 
     The United States Department of Agriculture (USDA) National Institute of Food and 
Agriculture (NIFA) sponsors the Minor Use Animal Drug Program as the National Research 
Support Project-7 (NRSP-7) which provides funding to investigate drugs for potential use in 
minor species and for minor uses in major species (USDA National Research Support Project 
7, 2007).
 
 Tulathromycin, a novel triamilide antibiotic in the macrolide class, has been shown 
to be safe and efficacious in the treatment of bacterial respiratory disease in cattle and swine 
(Evans, 2005; Nowakowski et al., 2004; Hart et al., 2006).   A single injection provides 
seven days of therapeutic concentrations in lung tissues in these species.  The drug has 
demonstrated efficacy against respiratory pathogens shared by cattle and goats; therefore, 
tulathromycin has been selected for an NRSP-7- supported project.  As part of the larger 
supported project, the objective of this study was to identify antimicrobial susceptibility 
patterns in bacterial respiratory pathogens from goats with clinical pneumonia and to 
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specifically evaluate susceptibility of these isolates to tulathromycin using two in vitro 
methods.   
Materials and methods 
Bacterial isolates—The isolates in this study were collected from diagnostic laboratories 
from various geographic regions throughout the United States.  All isolates were recovered 
from diseased pulmonary tissues from goats with clinical respiratory disease.  Forty-five M. 
haemolytica, eleven P. multocida, and eleven B. trehalosi isolates were identified by growth 
and biochemical characteristics and stored in brain heart infusion (BHI) broth containing 
glycerol at -80
o
 C.   
Blinding and Randomization—Isolates were assigned a random study designation upon 
arrival at the laboratory.  All isolates included in the study met the source criteria—collected 
from diseased tissues in goats suffering from respiratory disease.  All persons conducting 
susceptibility testing of the isolates had no knowledge about results of previous testing done 
on any of the isolates.   
MIC testing—Susceptibility determinations were performed by microbroth dilution 
methods using Sensititre (Trek Diagnostic Systems, Cleveland, OH).  Minimum inhibitory 
concentration (MIC) determinations were performed in accordance with criteria provided in 
M31 [A3] (Clinical Laboratory Standards Institute [CLSI], Wayne, PA).   Isolates were 
tested against 14 antimicrobials at the listed dilutions, including ampicillin (0.25-16µg/ml), 
ceftiofur (0.25-8 µg/ml), chlortetracycline (0.5-8 µg/ml), danofloxacin (0.12-1 µg/ml), 
enrofloxacin (0.12-2 µg/ml), florfenicol (0.25-8 µg/ml), gentamicin (1-16 µg/ml), neomycin 
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(4-32 µg/ml), oxytetracycline (0.5-8 µg/ml), penicillin (0.12-8 µg/ml), sulfadimethoxine (256 
µg/ml), trimethoprim-sulfamethoxazole (2/38 µg/ml), tulathromycin (1-64 µg/ml), and 
tylosin (0.5-32 µg/ml).  Escherichia coli ATTC 25922, Pseudomonas aeruginosa ATTC 
27853, Enterococcus faecalis ATTC 29212, and Staphylococcus aureus ATTC 29213 were 
used as quality control organisms.   
Bacterial isolates were sub-cultured on blood agar and incubated for 18-24 hours at 35˚C.  
Each isolate was suspended in phosphate-buffered saline (PBS) to a concentration equivalent 
to a 0.5 McFarland standard and 10µl of this standard was added to 10ml of broth for 
antimicrobial susceptibility plate inoculation.  Cation-adusted Mueller-Hinton broth 
containing 100μl of fetal calf serum was used for P. multocida testing; Cation-adusted 
Mueller-Hinton broth containing lysed horse blood was used for M. haemolytica and B. 
trehalosi testing.  Susceptibility plates were incubated for 18 hours at 35˚C and observed for 
visible growth.  The MIC was determined as the lowest concentration of antimicrobial that 
prevented visible growth.    All isolates were tested in duplicate on different days; isolates 
with any discrepancy in tulathromycin MIC were tested in triplicate so a consensus MIC 
value could be obtained.   
In order to assess bactericidal effects of tulathromycin, an aliquot of each MIC sample 
well containing a dilution of tulathromycin was plated onto media without antimicrobial and 
incubated at 37˚C overnight to determine if bacterial growth had been inhibited or if 
bactericidal effects could be seen with the given concentration of tulathromycin (MBC100).   
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Statistical analysis—MIC results were stratified for each species of bacteria and 
summarized; mode value and range were determined for each antimicrobial.  Stratified 
analysis with the nonparametric Kruskal-Wallis test was used to compare tulathromycin 
MIC’s between bacterial species.  Interpretations of MIC breakpoints were extrapolated 
based on CLSI criteria for bacterial species associated with bovine respiratory disease 
complex (BRDC) and were compared for each antimicrobial between the bacterial species.  
“Percent susceptible” was calculated as the number of isolates classified as “susceptible” 
divided by the total number of isolates tested and expressed as a percentage.  Statistical 
comparisons were made of the percent susceptible for each drug between species using 
Fisher’s exact test using SAS statistical software (version 9.1, SAS Institute, Inc., Cari, NC). 
Kinetic killing assay—To further evaluate the susceptibility of these isolates to 
tulathromycin, kinetic killing assays were conducted to determine the percentage of bacteria 
killed within two hours at a given tulathromycin concentration with a goal of establishing the 
minimum bactericidal concentration that resulted in > 99% of bacterial die off (MBC99) 
during this period.   Since the maximum MIC concentration for all isolates was 8µg/ml, this 
concentration was chosen for initial kinetic killing assays.  Eleven randomly selected M. 
haemolytica isolates as well as the eleven P. multocida and eleven B. trehalosi isolates were 
sub-cultured on blood agar and incubated for 18-24 hours at 35˚C.  A heavy inoculum was 
made of each isolate in sterile BHI broth containing 5% serum and 0.05% yeast and placed in 
a shaking incubator at 37˚C and 160 RPM for 60 minutes to establish a rapidly growing 
bacterial suspension.  A starting inoculum of 0.280 at OD595 for M. haemolytica and P. 
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multocida and 0.350 at OD595 for B. trehalosi that corresponded to 1 X 10
8
-1 X 10
9
 cfu/ml 
was incubated at 37˚C with 8 μg/ml of tulathromycin.  Aliquots of this culture suspension 
were removed and colony count assays performed at time = 0, 30 minutes, 60 minutes, 90 
minutes, and 120 minutes for each isolate.  Additionally, five (three P. multocida and two B. 
trehalosi) isolates that had <99% bacterial kill at 2 hours when tested at 8 µg/ml were tested 
against a tulathromycin suspension of 16 μg/ml with the same collection time points. 
Quality assurance was provided in accordance with Good Laboratory Practices (21 CFR 
Part 58). 
Results 
Results of univariate analysis of MIC values for each antimicrobial and bacterial species 
are listed in Table 5.1.  Most isolates demonstrated low MIC values against antimicrobials 
tested; however, a few isolates had values at the high end of the tested range.  Differences 
between species in MIC value were detected for ampicillin (between all species),   
chlortetracycline (between all species), danofloxacin (between B. trehalosi and the other 
species), florfenicol (between all species), gentamicin (between P. multocida and the other 
species), neomycin (between P. multocida and the other species), oxytetracycline (between 
all species), penicillin (between all species), tulathromycin (between all species), and tylosin 
(between P. multocida and the other species).  No isolates that were tested in triplicate had an 
MIC result that varied by more than one dilution in repeat testing.   
Utilizing the susceptibility definitions established for these bacteria in bovine respiratory 
disease, interpretations were determined for these isolates and are listed in Table 5.2.  Most 
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of the caprine isolates showed high levels of susceptibility to most of the antimicrobials 
tested.  Notable exceptions include penicillin (M. haemolytica, 13.3% susceptible; P. 
multocida, 72.7% susceptible; B. trehalosi, 0% susceptible); tetracycline (B. trehalosi, 45.5% 
susceptible; and sulfadimethoxine (P. multocida, 45.5% susceptible).  
One hundred percent of these isolates were classified as susceptible to tulathromycin.  
Comparison of results of MIC and MBC100 testing of tulathromycin in each bacterial species 
is shown in Figure 5.1.  In all three bacterial species, many of the isolates had MIC and 
MBC100 values that were identical (M. haemolytica 34/45, 53.3%; P. multocida 9/11, 81.8%; 
B. trehalosi 5/11, 45.5%).   
Kinetic assays further demonstrated that 100% of M. haemolytica isolates tested had 
MBC99 at 8 μg/ml; 72.7 (8/11) of P. multocida isolates had MBC99 at 8 μg/ml with an 
additional two isolates (18.2%) having a MBC99 at 16 μg/ml; and 63.6% (7/11) and 27.3% 
(3/11) of B. trehalosi isolates with a MBC99 of 8 μg/ml and 16 μg/ml, respectively.    The 
remaining B. trehaolosi isolate had a 98.0% decrease in colony counts after two hours of 
contact with 8 μg/ml of tulathromycin while the last P. multocida isolate showed a 96.7% 
decrease with 16 μg/ml of tulathromycin suspension over this same time period.  Results  of 
kinetic assays are summarized in Figure 5.2. 
Discussion 
Although no CLSI guidelines for MIC breakpoints have been established for bacterial 
species from goats, application of susceptibility guidelines for cattle pathogens to the same 
agents recovered from goats suggest that these bacteria remain relatively susceptible to most 
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commonly-used antimicrobials in veterinary medicine. MIC values showed some differences 
between and within bacterial species, but interpretations of susceptibility versus resistance 
were very similar.  This indicates that mechanisms of antimicrobial resistance do not appear 
to be widespread in goat respiratory pathogens.  Interestingly, B. trehalosi isolates 
demonstrated a greater resistance to the tetracycline drugs tested than the other bacteria 
species while P. multocida showed marked resistance to sulfadimethoxine.  High level 
resistance to penicillin was seen in all three species. 
Macrolide antimicrobials are characterized by rapid dissemination out of plasma and into 
lung, making them useful in the treatment of bacterial pneumonia (Williams & Sefton, 1993).  
Newer macrolides such as tulathromycin have been developed that provide improved lung 
tissue penetration and extended half lives.(Benchaoui et al., 2004; Evans, 2005)  Bactericidal 
antimicrobials have MIC values that are very close to MBC values, while bacteriostatic drugs 
have MBC that are much greater than MIC values (Andrews et al., 2001).   In the present 
study, 63% of all isolates had MBC that were equal to their MIC for tulathromycin, 
indicating that tulathromycin demonstrates bactericidal activity.  Results of the kinetic killing 
assays further support the efficacy of tulathromycin against respiratory bacterial pathogens.   
Bactericidal compounds have been defined by the ability to provide a 99% reduction in 
colony number in an in vitro assay (Dorfman et al., 2008).  While MIC and MBC100 assays 
evaluate the effect of a drug over a 18-24 hour incubation period, kinetic kill assays more 
directly measure the degree of bacterial killing at given concentrations of antimicrobial over 
a short time period (Dorfman et al., 2008).    Rapid killing of caprine respiratory pathogens 
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seen in the kinetic kill assays of this study provided further evidence of tulathromycin 
efficacy against these agents.   
Results of this study indicate that goat respiratory bacterial pathogens remain susceptible 
to the most commonly prescribed antibiotics in veterinary medicine, and that tulathromycin 
could be a useful antimicrobial against caprine respiratory pathogens.  The benefits of 
extended therapeutic activity from a single injection could prove valuable in this species. 
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Table 5.1.  Summary statistics of MIC values and P-values for differences in antimicrobial 
susceptibility between bacterial species for M. haemolytica, P. multocida, and B. trehalosi 
isolates collected from goat tissues against tested antimicrobials.    
  
 M. haemolytica P. multocida  B. trehalosi   
Antimicrobial Mode     Range Mode  Range Mode Range P-value 
Ampicillin < 0.25 < 0.25-0.5 < 0.25 < 0.25 0.5 < 0.25- >16  < 0.001 
Ceftiofur < 0.25 < 0.25 < 0.25 < 0.25 < 0.25 < 0.25 1.000 
Chlortetracycline < 0.5 < 0.5-8 < 0.5 < 0.5 < 0.5-8 < 0.5-8 < 0.001 
Danofloxacin < 0.12 < 0.12-0.25 < 0.12 < 0.12 < 0.12 < 0.12- >1 0.020 
Enrofloxacin < 0.12 < 0.12-0.5 < 0.12 < 0.12 < 0.12 < 0.12-1 0.389 
Florfenicol  1        0.5-1 < 0.25 < 0.25-0.5 0.5 0.5-1 < 0.001 
Gentamicin  2         2-4 < 1 < 1-2 2 < 1-2 < 0.001 
Neomycin < 4 < 4-8 < 4 < 4 8 < 4-16 0.005 
Oxytetracycline < 0.5 < 0.5->8 < 0.5 < 0.5-2  8 < 0.5- >8 < 0.001 
Penicillin  0.5 < 0.12->8 < 0.12 < 0.12-0.5 1 0.5- >8 < 0.001 
Sulfadimethoxine < 256 < 256->256 < 256 < 256->256 <256 < 256 0.231 
Trimethoprim-  
  Sulfamethoxazole  < 2 < 2 < 2 < 2 < 2 < 2  1.000 
Tulathromycin 4   2-8    2 < 1-4 4 2-4 < 0.001 
Tylosin 32 32->32  32  16-32 > 32  32->32 < 0.001 
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Table 5.2.  Percent of isolates interpreted as susceptible and P-value for statistical differences 
between isolates of M. haemolytica, P. multocida, and B. trehalosi collected from goats with 
pneumonia for individual antibiotics. 
 
   M. haemolytica P. multocida  B. trehalosi P-value 
         n = 45     n = 11     n = 11   
Ampicillin 97.8 100.0  90.1 0.224 
Ceftiofur 100.0 100.0 100.0 1.000 
Chlortetracycline  93.3 100.0 45.5 < 0.001 
Danofloxacin 100.0 100.0 90.1 0.162 
Enrofloxacin  97.8 100.0 90.1 0.224 
Florfenicol 100.0 100.0 100.0 1.000 
Gentamicin 100.0 100.0 100.0 1.000 
Neomycin 97.8 100.0 90.1 0.224 
Oxytetracycline 93.3 100.0 45.5 < 0.001 
Penicillin 13.3 72.7  0 < 0.001 
Sulfadimethoxine 91.1 45.5 10.0.0 0.0002 
Trimethoprim/     
   sulfamethoxazole 100.0 100.0 100.0 1.000 
Tulathromycin 00.0 100.0 100.0 1.000 
Tylosin  0     0  0 1.000 
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Figure 5.1. Percent of isolates with minimum inhibitory concentrations (MIC) and 
minimum bactericidal concentrations (MBC) for tulathromycin against M. haemolytica, 
P. multocida, and B. trehalosi isolates recovered from goats with clinical pneumonia. 
 
 Figure 5.2.  Results of kinetic killing assays evaluating the tulathromycin concentration 
associated with 99% bacterial killing (MBC99) in the first two hours of exposure for M. 
haemolytica, P. multocida, and B. trehalosi isolates recovered from goats with clinical 
pneumonia. 
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CHAPTER 6.  CONCLUSIONS AND FUTURE RESEARCH 
This manuscript describes the results of studies conducted in order to support the FDA 
requirements for tulathromycin approval to treat bacterial pneumonia in goats.  The TAS 
study findings were consistent with those of Washburn et al., (2007), and determined that no 
detrimental effects could be attributed to tulathromycin administration, even at five times the 
label dose and three times the label duration for cattle and swine.  Our study was performed 
in very young goat kids rather than in adult goats under the assumption that the younger 
animals would be most likely to manifest adverse effects due to tulathromycin overdose. Our 
study took safety evaluation further to ensure no detrimental effects associated with 
tulathromycin could be detected on gross necropsy, histologic exam or clinical pathology.  
For human food safety evaluation, tissue residue analysis was performed on three separate 
groups of goats:  the goats from the TAS study; goats used in a preliminary study to ensure 
that adequate pharmacokinetic and tissue collection procedures could be established for 
subsequent large studies; and market-age goats that would be most likely to enter the human 
food chain.  The tissue residue studies provide information to support the establishment of a 
withdrawal period following administration of tulathromycin by a subcutaneous route. Since 
methods of assessing efficacy in cattle and swine were not amenable to goat production 
systems, alternative parameters of plasma tulathromycin analysis, lung tissue tulathromycin 
analysis, and in vitro bacterial susceptibility to tulathromycin were used to establish 
AUC/MIC ratios against the most commonly recovered bacterial pathogens in goats.   
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While adequate numbers of M. haemolytica isolates were collected to meet the minimum 
FDA requirements, only 11 P. multocida and 11 B. trehalosi isolates, and 9 Mycoplasma 
isolates were located.  Future work will be aimed at identifying additional isolates of these 
species for testing and to creating a tulathromycin assay that can be used to establish MIC 
values for Mycoplasma isolates.   
Additional studies could be conducted that measure the tulathromycin concentrations in 
specific aspects of the lung tissue.  Alveolar macrophages have been used as a representative 
cell type recruited during the immune response to a bacterial infection.  Evaluation of the 
tulathromycin concentration in this specific cell type may provide more precise 
measurements of the drug available at the site of bacterial infections in the lung; however, 
this type of evaluation would not account for tulathromycin present in other immune cells 
such as neutrophils nor does it provide information about drug presence in extracellular 
spaces such as interstitial fluid or endothelial secretions.  Serial collection of pulmonary 
macrophages retrieved via broncho-alveolar lavage sampling for tulathromycin analysis may 
not yield an accurate representation of drug concentrations since the collection process will 
incite an influx of inflammatory cells, particularly macrophages.   
In cattle and swine studies, lung tissue homogenates were used to assess total 
tulathromycin concentrations.  Similar procedures were utilized in these goat studies to 
facilitate comparison of results and demonstrated that total drug exposure was similar 
between the species.  Given the pharmacokinetic and pharmacodynamic similarities of 
tulathromycin between species, one could reasonably predict that tulathromycin should be 
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just as efficacious in goats as it has proven to be in cattle and swine.  Reports from the field 
where tulathromycin has been used in caprines under veterinary prescription according to 
AMDUCA regulations also indicate that tulathromycin is proving to be a valuable 
antimicrobial for use against bacterial respiratory infections. 
Information collected in the present studies can also be used to provide predictive models 
for use in extrapolation to other species, particularly other species such as sheep, llamas, 
alpacas, and deer.  While extrapolation of drug behavior between species is less desirable 
than actual studies in the target species, it can provide guidance for veterinarians who 
prescribe antimicrobials under AMDUCA requirements to other minor species.  Data from 
the studies in caprines may also be useful in designing protocols for studies to be conducted 
in other species and facilitate adherence to FDA requirements for approval of tulathromycin 
in these species. 
The FDA CVM is responsible for ensuring the safety and efficacy of all drugs labeled for 
use in animals in the United States.  Requirements maintained by the FDA for approval are 
justifiably strict, specifying that a given drug be evaluated in a specific species to treat an 
individual condition or set of conditions.  Only by utilizing such defined criteria and 
maintaining rigorous standards for evaluation of potential medications can the FDA ensure 
that a product has been adequately investigated for safety, efficacy, and potential effects on 
humans before it is released onto the market.  While the AMDUCA gives veterinarians the 
authority to prescribe a drug when deemed medically necessary under a valid veterinary-
client-patient relationship, this directive places the responsibility for any effects of this drug 
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on the veterinarian.  Without adequate data from controlled scientific studies, veterinarians 
may prescribe compounds which produce unintended consequences in animals being treated 
or result in undesired products entering the human food chain.  Minor species or uncommon 
conditions present unique challenges for veterinarians.  Extrapolation of data from similar 
species, computer simulations, and mathematical modeling can be useful in guiding 
veterinarians in drug administration; however, these techniques cannot provide the same 
level of critical assessment that can be gained from studies evaluating a specific medication 
in the target species to be treated. 
As more is learned about the development of antimicrobial resistance in bacterial isolates 
and its relationship with antibiotic resistance in human and animal pathogens, future 
restrictions on drug use is to be expected.  Careful evaluation of risks and benefits of 
antimicrobial use along with critical scientific assessments of these drugs will ensure that 
they are prescribed in the most judicious manner while minimizing the potential for side 
effects.  FDA guidelines are designed to provide this critical assessment and will help to 
ensure that only safe and effective medications with adequately-defined withdrawal periods 
enter the marketplace.  It is to the benefit of the veterinary profession as well as to 
agricultural industries to ensure that these strict regulations are respected and adhered to in 
order to ensure that high quality animal-derived products without drug residues enter human 
product markets. 
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